Language selection

Search

Patent 1311201 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1311201
(21) Application Number: 1311201
(54) English Title: DESAZAPURINE-NUCLEOSIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE THEREOF FORNUCLEIC ACID SEQUENCING AND AS ANTIVIRAL AGENTS
(54) French Title: DERIVES DESAZAPURINE-NUCLEOSIDE, PROCEDE POUR LEUR PREPARATION, COMPOSITIONS PHARMACEUTIQUES EN CONTENANT ET LEUR UTILISATION POUR LE SEQUENCAGE DE L'ACIDE NUCLEIQUE ET COMME ANTIVIRAUX
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07H 19/16 (2006.01)
  • A61K 31/70 (2006.01)
  • C07D 405/14 (2006.01)
  • C07D 471/04 (2006.01)
  • C07D 487/04 (2006.01)
  • C07H 19/14 (2006.01)
  • C07H 19/20 (2006.01)
(72) Inventors :
  • SEELA, FRANK (Germany)
  • MUTH, HEINZ-PETER (Germany)
  • KAISER, KLAUS (Germany)
  • BOURGEOIS, WERNER (Germany)
  • MUHLEGGER, KLAUS (Germany)
  • VON DER ELTZ, HERBERT (Germany)
  • BATZ, HANS-GEORG (Germany)
(73) Owners :
  • BOEHRINGER MANNHEIM GMBH
(71) Applicants :
  • BOEHRINGER MANNHEIM GMBH (Germany)
(74) Agent: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.
(74) Associate agent:
(45) Issued: 1992-12-08
(22) Filed Date: 1988-04-08
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
S.N. P 37 12 280.0 (Germany) 1987-04-10
S.N. P 37 39 366.9 (Germany) 1987-11-20

Abstracts

English Abstract


ABSTRACT
Desazapurine-nucleoside derivatives, processes for the
preparation thereof, pharmaceutical compositions
containing them and the use thereof for nucleic acid
sequencing and as antiviral agents
The present invention provides desazapurine-
nucleoside derivatives of the general formula:-
(I)
<IMG>
wherein X is a nitrogen atom or a methine radical, W is
a nitrogen atom or a <IMG> radical, R1, R2, R3 and R4,
which can be the same or different 3 are hydrogen or
halogen atoms, hydroxyl or mercapto groups, lower alkyl,
lower alkylthio, lower alkoxy, aralkyl, aralkoxy or
aryloxy radicals or amino groups optionally substituted
once or twice, R5 is a hydrogen atom or a hydroxyl group,
R6 and R7 are each hydrogen atoms or one of them is a
halogen atom or a cyano or azido group or an amino group
optionally substituted once or twice, whereby one of
R6 and R7 can also be a hydroxyl group when X is a
methine radical and, in addition, R5 and R7 can together

also represent a further valency bond between C-2'
and C-3' and is a hydrogen atom or a mono-, di- or
tri-phosphate group, as well as the tautomers and
salts thereof and nucleic acids which contain one
or more compounds of general formula (I) as
structural components; these new compounds are use-
ful for nucleic acid sequencing and as antiviral
agents.


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiments of the invention in which an exclusive
property or privilege is claimed are defined as
follows:
1. Desazapurine-nucleoside derivatives of the
general formula:-
(I)
<IMG>
wherein X is a nitrogen atom or a methine radical; W
is a nitrogen atom or a <IMG> radical, R1, R2, R3 and
R4, which can be the same or different, are hydrogen
or halogen atoms, hydroxyl or mercapto groups, lower
alkyl, lower alkylthio, lower alkoxy, aralkyl,
aralkoxy, aryloxy, unsubstituted amino, or amino
substituted once or twice by C1-C5 alkyl or C1-C5
alkyl substituted once or twice by C1-C5 alkoxy,
halogen or amino; R5 is a hydrogen atom or a hydroxyl
group; R6 and R7 are each hydrogen atoms or one of
them is a halogen atom, cyano or azido, unsubstituted
amino, or amino substituted once or twice by C1-C5
alkyl or C1-C5 alkyl substituted once or twice by
C1-C5 alkoxy, halogen or amino; and one of R6 and R7
can also be a hydroxyl group when X is a methine
radical and, in addition R5 and R7 can together also
62

represent a further valency bond between C-2' and
C-3'; and Y is a hydrogen atom or a mono-, di- or
tri-phosphate group, as well as the tautomers and
salts thereof and nucleic acids which contain one or
more compounds of general formula (I) as structural
components, provided that when X is nitrogen, W is
CR4, and R1 is amino, at least one of Y, R2, R3, R4,
R5, R6 and R7 is other than hydrogen;
and provided that when X and W are methine and
R1 and R2 are both chlorine and R is hydroxy at least
one of Y, R3, R5 and R7 is other than hydrogen;
and provided that when X is methine, W is
nitrogen, R1 and R6 are hydroxyl and R2 is amino, at
least one of Y, R3, R5 and R7 is other than hydrogen.
2. A nucleic acid containing one or more
desazapurine nucleoside derivatives of formula (I), as
defined in claim 1.
3. A nucleic acid according to claim 2, comprising
2 to 1000 nucleotide structural components.
4. A nucleic acid according to claim 2, comprising
8 to 50 nucleotide structural components.
5. A nucleic acid according to claim 2, comprising
15 to 30 nucleotide structural components.
63

6. A derivative of claim 1, wherein said aralkyl
is benzyl.
7. A derivative of claim 1, wherein said aryloxy
radical is phenyloxy.
8. A derivative of claim 1, wherein at least one
of R1, R2, R3, R4, R6 and R7 is amino.
9. A derivative of claim 1, wherein at least one
of R1, R2, R3, R4, R5, R6 and R7 is substituted at
least once by an alkyl radical with from 1 to 5 carbon
atoms.
10. A derivative of claim 1, wherein at least one
of R1, R2, R3 and R4 is aralkyl.
11. A derivative of claim 1, wherein X is methine
and at least one of R6 and R7 is hydroxy.
12. 2-Amino-7-desaza-2',3'-didesoxy-9-beta-D-ribo-
furanosyl-purine-6-one.
64

13. 6-Amino 8-aza-7-desaza-2',3'-didesoxy-9-beta-D-
ribofuranosylpurine.
14. 3,7-Didesaza-2',3'-didesoxy-9-beta-D-ribofurano-
syl-purine-6-one.
15. 7-(2',3'-Didesoxy-beta-D-glyceropentofuranosyl)-
7H-pyrrolo[2,3-d]pyrimidine.
16. 4-Amino-7-(2',3'-didesoxy-beta-D-glyceropento-
furanosyl)-7H-pyrrolo[2,3-d]pyrimidine.
17. A pharmaceutical composition comprising at
least one compound of formula I
(I)
<IMG>
wherein X is a nitrogen atom or a methine radical; W
is a nitrogen atom or a <IMG> radical; R1, R2, R3, and
R4, which can be the same or different, are hydrogen

or halogen atoms, hydroxyl or mercapto groups, lower
alkyl, lower alkylthio, lower alkoxy, aralkyl,
aralkoxy, aryloxy, unsubstituted amino, or amino
substituted once or twice by C1-C5 alkyl or C1-C5
alkyl substituted once or twice by C1-C5 alkoxy,
halogen or amino; R5 is a hydrogen atom or a hydroxyl
group; R6 and R7 are each hydrogen atoms or one of
them is a halogen atom, cyano or azido, unsubstituted
amino, or amino substituted once or twice by C1-C5
alkyl or C1-C5 alkyl substituted once or twice by
C1-C5 alkoxy, halogen or amino, and one of R6 and R7
can also be a hydroxyl group when X is a methine
radical and, in addition R5 and R7 can together also
represent a further valency bond between C-2' and
C-3'; and Y is a hydrogen atom or a mono-, di- or
tri-phosphate group, or a tautomer thereof, or a
pharmaceutically acceptable, pharmacologically
compatible salt thereof, provided that when X is
nitrogen, W is CR4, and R1 is amino, at least one of
Y, R2, R3, R4, R5, R6 and R7 is other than hydrogen;
and provided that when X and W are methine and
R1 and R2 are both chlorine and R6 is hydroxy at least
one of Y, R3, R5 and R7 is other than hydrogen;
66

and provided that when X is methine, W is
nitrogen, R1 and R6 are hydroxyl and R2 is amino, at
least one of Y, R3, R5 and R7 is other than hydrogen
in association with a pharmaceutically acceptable
carrier.
18. An antiviral pharmaceutical composition
comprising an acceptable, effective antiviral amount
of a desazapurine-nucleoside derivative of formula (I)
<IMG>
wherein X is a nitrogen atom or a methine radical; W
is a nitrogen atom or a <IMG> radical; R1, R2, R3 and
R4, which can be the same or different, are hydrogen
or halogen atoms, hydroxyl or mercapto groups, lower
alkyl, lower alkylthio, lower alkoxy, aralkyl,
aralkoxy, aryloxy, unsubstituted amino, or amino
substituted once or twice by C1-C5 alkyl or C1-C5
alkyl substituted once or twice by C1-C5 alkoxy,
67

halogen or amino; R5 is a hydrogen atom or a hydroxyl
group; R6 and R7 are each hydrogen atoms or one of
them is a halogen atom, cyano or azido, unsubstituted
amino, or amino substituted once or twice by C1-C5
alkyl or C1-C5 alkyl substituted once or twice by
C1-C5 alkoxy, halogen or amino; and one of R6 and R7
can also be a hydroxyl group when X is a methine
radical and, in addition R5 and R7 can together also
represent a further valency bond between C-2' and
C-3'; and Y is a hydrogen atom or a mono-, di- or
tri-phosphate group, or a tautomer thereof, or a
pharmaceutically acceptable, pharmacologically
compatible salt thereof, provided that when X is
nitrogen, W is CR4, and R1 is amino, at least one of
Y, R2, R3, R4, R5, R6 and R7 is other than hydrogen;
and provided that when X and W are methine and
R1 and R2 are both chlorine and R6 is hydroxy at least
one of Y, R3, R5 and R7 is other than hydrogen;
and provided that when X is methine, W is
nitrogen, R1 and R6 are hydroxyl and R2 is amino, at
least one of Y, R3, R5 and R7 is other than hydrogen
in association with a pharmaceutically acceptable
carrier therefor.
68

19. A composition according to claim 18 containing
an amount of said derivative (I), or salt thereof,
effective to inhibit reverse transcriptase.
20. In a method of DNA sequencing according to
Sanger's method, the improvement in which there is
employed a derivative of formula (I)
(I)
<IMG>
wherein X is a methine radical,
W is a nitrogen atom or a <IMG> radical; R1,
R2, R3 and R4, which can be the same or different, are
hydrogen or halogen atoms, hydroxyl or mercapto
groups, lower alkyl, lower alkylthio, lower alkoxy,
aralkyl, aralkoxy, aryloxy, unsubstituted amino, or
amino substituted once or twice by C1-C5 alkyl or
69

C1-C5 alkyl substituted once or twice by C1-C5 alkoxy,
halogen or amino; R5 is a hydrogen atom or a hydroxyl
group;
R6 is hydroxyl;
R7 is a hydrogen atom, halogen atom, cyano,
azido, unsubstituted amino, or amino substituted once
or twice by C1-C5 alkyl or C1-C5 alkyl substituted
once or twice by C1-C5 alkoxy, halogen or amino; or
R5 and R7 together represent a further valency
bond between C-2' and C-3'; and Y is a hydrogen atom
or a mono-, di- or tri-phosphate group, or a tautomer
thereof.
21. In a method of DNA sequencing employing a chain
terminator in accordance with Sanger's method, the
improvement in which the chain terminator is a
derivative of formula (I)
(I)
<IMG>

wherein X is a nitrogen atom or a methine radical;
W is a nitrogen atom or a <IMG> radical; R1,
R2, R3 and R4, which can be the same or different, are
hydrogen or halogen atoms, hydroxyl or mercapto
groups, lower alkyl, lower alkylthio, lower alkoxy,
aralkyl, aralkoxy, aryloxy, unsubstituted amino, or
amino substituted once or twice by C1-C5 alkyl or
C1-C5 alkyl substituted once or twice by C1-C5 alkoxy,
halogen or amino; R5 is a hydrogen atom or a hydroxyl
group;
R6 and R7 are both hydrogen atoms, and Y is a
hydrogen atom or a mono-, di- or tri-phosphate group,
or a tautomer thereof, in which R6 and R7 are hydrogen
atoms.
22. A desazapurine-nucleoside derivative of formula
(I), as defined in claim 1, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15 or 16, or a tautomer thereof, or a
pharmaceutically acceptable, pharmacologically
compatible salt thereof, for use in the inhibition of
the enzyme reverse transcriptase.
23. Use of a desazapurine-nucleoside derivative of
formula (I), as defined in claim 1, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15 or 16, or a tautomer thereof, or a
71

pharmaceutically acceptable, pharmacologically
compatible salt thereof, for the manufacture of a
medicament for the treatment of virus infections.
24. Use of a desazapurine-nucleoside derivative of
formula (I), as defined in claim 1, 6, 7 or 10,
wherein R6 is a hydroxyl group and W is a methine
radical, or a tautomer thereof, for DNA sequencing
according to Sanger's method.
25. Use of a desazapurine-nucleoside derivative of
formula (I), as defined in claim 1, 6, 7 or 10, in
which R6 and R7 are hydrogen atoms, or a tautomer
thereof, for DNA sequencing according to Sanger's
method.
26. A pharmaceutical composition comprising an
effectively acceptable amount of a derivative defined
in claim 6, 7, 8, 9, 10 or 11, or a tautomer thereof,
or a pharmaceutically acceptable, pharmacologically
compatible salt thereof, in association with a
pharmaceutically acceptable carrier.
72

27. A pharmaceutical composition comprising an
effective, acceptable amount of a compound of claim
12, 13, 14, 15 or 16, in association with a
pharmaceutically acceptable carrier.
28. An antiviral pharmaceutical composition
comprising an acceptable, effective antiviral amount
of a derivative as defined in claim 6, 7, 8, 9, 10 or
11, or a tautomer thereof, or a pharmaceutically
acceptable, pharmacologically compatible salt thereof,
in association with a pharmaceutically acceptable
carrier.
29. An antiviral pharmaceutical composition
comprising an acceptable, effective antiviral amount
of a compound of claim 12, 13, 14, 15 or 16, in
association with a pharmaceutically acceptable
carrier.
73

Description

Note: Descriptions are shown in the official language in which they were submitted.


2 ~ ~
1 --
The present invention is concerned with new des-
azapurine-nucleoside derivatives~ processes for the
preparation thereof, as well as the use tllereof in the
sequencing of nucleic acids, and also as anti-viral
agen.s.
The new desazapurine-nucleoside derivatives accord-
ing to the present invention are compounds of the
general formula:-
Rl R3
N
R2 l X ~
R7 R5¦
~' Y-O~O~
.' ~
R6
wh~rein X is a nitrogen atom or a methine group, W is
~; a nitrogen atom or a ~ C-R4 radical, p~l, R2, R3 and R4,
which can be the same or diferent, are hydrogen or
halogen atoms, hydroxyl or mercapto groups, lower alkyl,
lower alkylthio, lower alkoxy, aralkyl, aralkoxy or
aryloxy radicals or amino groups optionally substituted
once or twice, R5 is a hydrogen atom or a hydroxyl group
and R6 and R7 are each hydrogen atoms or one of them is
~:~ a halogen atom or a cyano or azido group or an amino
group optionally substituted once or ~wice, whereby one
o~ R6 and R7 can also be a hydroxyl group when X is a
methine radical and, in addition, R5 and R7 can together
' ' ' '

~ 3 ~
-- 2 --
represent a further valency bond between C-2' and C-3'
and Y is a hydrogen atom or a mono-, cli- or triphosphate
group1 as well as the tautomers and salts thereof and
nucleic acids which contain compounds of general
formula I as structural co~ponents.
The lower alkyl radicals in the definition of ~he
substituents Rl, R2, R3 and R4 can be saturated or
unsaturated, straight-chained or branched and contain
up to 7 and preerably up to 4 carbon atoms. This
definition of the alkyl radicals also applies to the
alkyl moieties which occur in the definitions of the
lower alkylthio and lower alkoxy radicals, The methyl
and ethyl radicals are quite especially prefe~red.
By halogen in the defini~ion of the substituents
Rl, R~, R39 R4, R6 and R7 are to be tmderstood fluorineg
chlorine, bromine and iodine.
~ The aralkyl and aralkoxy radicals in the
: definitions of the substituents R , R , R and R
contain an alkyl moiety with up to 5 and preferably
with up to 3 carbon a-toms which are substituted
one or more times with an aryl moiety suitably of
6 to 10 carbon atoms, for example, a phenyl or
naphthyl radical. The aromatic radicals can, in
turn, be substituted one or more times by an alkyl
or alkoxy radical. The benzyl radical is especially
preferred.

-- 3 --
The aryl moiety of the aryloxy radical in the
definition of Rl, R , R and R , suitably has 6 to
10 carbon atoms, the phenyloxy radical being
especially preferred which canop-tionally be sub-
stituted one or more times by further substituents,
for example, nitro groups and alkyl and alkoxy
radicals.
The amino group occurring in the definition of
R , R , R , R , R and R , which can op-tionally be
substituted onceor twice, contains, as possible sub-
stituents, preferably alkyl radicals with up to 5
and preferably up to 3 carbon atoms which, in turn,
can be substitu-ted by lower alkoxy radicals, halogen
atoms or amino groups optionally substituted once or
twice. I'hese substitutents can also represent an
aralkyl radical with an alkyl moiety of up to 5, pre~
ferably up to 3 carbon atoms and an aryl moiety of 6
to 10 carbon atoms. The two nitrogen substituents
can together also represent an alkylidene radical
and preferably a methylidene radical which, in turn,
can be substituted by lower alkoxy, substituted amino
groups or halogen atoms. A quite especially preferred
substituent of this kind is the dimethylamino-
methylidene radical.
: ~ .

2 ~ ~
The monophosphate group is ~he -PO(OH)2 group,
the diphosphate group is the -P203(0H)3 group and ~he
triphosphate group is the P305~0H)4 group.
As possible salts, there are especially preferred
the alkali metal, alkaline earth metal and ammonium
salts of the phosphate groups. The alkaline earth metal
salts are especially the magnesium and calcium salts~
By ammonium salt~, according to the present invention
there are to be understood salts which contain the
~ 10 ammonium ion which can be substituted up to four times
: by alkyl radicals con~aining up to 4 carbon atoms and/or
by aralkyl radicale, preterably the benzyl radical. Th~
~, '' , ' ' .
.

3 A . 2 ~ ~
subs-tituents can hereby be the same or different. The
salts of ~he phospha~es can be converted in known
manner into the free acids.
The compounds of general formula I can contain
S basic groups, especially amino groups, which can be
converted into acid addition salts wi~h appropriate
acids, As acids for this purpose, there can be used,
for example, hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, fumaric acid, succinic
acid, tar~aric acid, citric acid, lactic acid, maleic
acid and methanesulphonic acid.
The compounds of general formula I are new. They
can be prepared analogously to known, related compounds.
For the preparation of the compounds of general formula
I, a process has proved to be especially preferred in
which a compound of the general formula:-
~l R3
(II)
R2 i X ~
Hin which X~ W, Rl~ R2 and R3 have the same meanings as
above, is reacted with a compound of the general
formula:-
R R
n~-o~ (III)
` R
-
.

- ~3~2~
--6--
in which R5 has the above-given meaning, R6 and R7
each represent hydrogen atoms or one of these two symbols
represents an azido group or a hydroxyl group protec~ed
by an oxygen protection group, R' is an oxygen
protection group and Z is a reactive group~ to give a
compound of the general formula:-
Rl R3
R2 1 x ~ N (IV)
~'_o~
R6 l
~: in which X~ W, Rl, R2, R3, R5, R6 , R7 and R' have the
above-given meanings 9 and oxygen protective groups
~;: 10 possibly present are split off and ~hereafter a compound
thus obtained, in which R6 or R7 is a hydroxyl group,
after selective protection of the 5'-hydroxyl group, is
optionally converted with a halide, cyanide or azide in known
manner into a compound of general formula I in which
R6 or R7 is a halogen atom or a cyano or azido group
or, in known manner, is deoxygenated to give a compound
of general formula I, in which R6 or R7 is a hydrogen
atom or a compound thus obtained of general formula I,
in which R6 or R7 is an azido group, is reduced in known
: 20 manner to a compound of general formula I in which R6
or R7 is an amino group and, if desired, a compound of
~ '
:

--7--
general forr.lula I, in which Y is a hyclrogen atom7 is
converted in known manner into a mono~, di- or tri-
phosphate and, if desired, a free base or acid obtained
is converted into an appropriate salt or a salt obtained
is converted into the corresponding free base or acid.
The compounds of general formula II are reacted
with the compounds of general formula III especially
advantageously under phase transfer conditions. Under
the conditions of phase transfer catalysis, t~e bases
of general formula II are converted into a corresponding
anion, for example by means of a 50% aqueous solution of
sodium hyd~oxide. The anion thus obtained is hydrophobed
by a phase transfer catalyst, for example tris-[2-(2-
methoxyethoxy)-ethyl]-amine, and transported into the
organic phase in which it reacts with the reac~ive
compound of general formula III.
As reactive groups Z in the compounds o~ general
formula III, there are preferably used halogen atoms
and alkoxy radicals. In the case of this reaction, the
hydroxyl groups of the sugar residue are protected in
the usual way by conventional oxygen protective groups,
for example toluoyl, benzoyl or aeetyl radicals. Af~er
completion of the reactionS the oxygen protective groups
- can again be split off in known manner under alkaline
conditions, a lM methanolic menthanolate solution prefer-
ably being used.
During ~he reaction, it can also be preferable to
.... .

2 ~ ~
-8-
keep the radicals Rl, R2, R3 and R4 protected by
appropriate protective groups.
Another advantageous method for the preparation
of compounds of general formula IV is the solid-liquid
phase transfer process with the use of solid, powd red
potassium hydroxide, the above-mentioned kryptand, as
well as compounds of general formulae II and III in an
aprotic solvent~
Compounds of general formula I 9 in which R6 or R7
is a halogen atom or an azido group, are preferably
prepared by starting from a compound of general formula
I, in which R6 or R7 is a hydroxyl group. The hydroxyl
group in the 5'-position is first to be selectlvely
protected. For this purpose, too~ known processes are
available. For example, in nucleotide chemistry, the
4,4'-dimethoxy-triphenylmethyl radical has proved to be
useful. After the reaction has taken place, this can
again be easily split of~ by mild acid hy~rolysis 9
whereas the also acid-labile glycosidic bond is not
hydrolysed under these conditions. The reaction of the
nucleoside to be protected with the oxygen protective
group reagent for the S'-hydroxyl grsup is carried out
in an appropriate organic solvent, preferably in dry
pyridine, with a small excess of the oxygen protective
group reagent 9 as well as possibly of an appropriate
adjuvant base 9 for example N-ethyldiisopropylamine.
The so protected compound of general formula I is

9~33 ~2~
reacted with a halide, preferably with an alkali ~etal
halide or an organic halide, or with an azide, prefer-
ably with an alkali metal azide, in known mannerO The
hydroxyl group on the C-3' atom is thereby nucleophilic-
ally substituted by the halide or azide.
Compounds of general formula I, in which R6 or R7
i9 a hydroxyl group, can also, af~er previous protection
of the 5'-hydroxyl group in the above-described manner,
be desoxygenated by known me~hods ~o give compounds of
general formula I, in which R6 and R7 are hydrogen atoms.
For this purpose~ the compound of general ormula I, in
which R6 or R7 is a hydroxyl group and in which the 5l~
hydroxyl group has been protected in the above-described
way and other functional radicals also carry protective
groups, is first converted into a 3'-0-thiocarbonyl
derivative which is subsequently reduced radically with
tributyl tin hydride. Such me~hods for the desoxygen-
ation of 2'-desoxynucleosides to giV8 2~ ,3'-didegoxy-
nucleosides are known, the 3arton desoxygenation method
having proved to be especially favourable (J. Chem. Soc.,
Perkin Trans. I (1975), 1574).
Compounds of general formula I, in which R6 or R7
is an amino group, are preferably prepared by reducing
a compound of general formula I, in which the substit-
uent R6 OI R7 is an azido group. This reduction of theazido group to the amino group can be carried out by
various ge~erally known methods, the reduction wi~h
.
,,~

-10-
hydrogen in the presence of a palladium-charcoal catalyst
having proved to be especially advantageous.
The phosphate groups are introduced in~o compounds
of general formula I, ln which Y is a hydrogen atom; in
known manner. The monophosphates are obtained, for
example, by phosphorylating compounds of general formula
I, in which Y is a hydrogen atom, with phosphorus oxy-
chloride in trimethyl phosphate. The triethylammonium
salts obtained in this way can be converted in known
manner into other salts by transsalification. The di-
and triphosphates are obtained according to known
preferably from the monophosphates, by reaction with
orthophosphates or pyrophosphates. Their various salts
can also be prepared by known methods.
Compounds of general formula II are either known
or can be prepared analogously to known compsunds. Such
methods of prepara~ion are described, for example, in
~ Chemische Berichte, 110, 1462~1977; J. Chem. Soc., 1460,
; 131; and Tetrahedron Letters, 21, 3135/1980.
Some of the compounds of general formulaIII are
also known. Compounds which have not hitherto been
described can be prepared completely analogously to the
known compounds. The preparation of such compounds îs
described, for example, in Chem. Ber., 93~ 2777/1960
25 and in Synthesis, 1984, 961.
The new compounds according to the present
invention possess valuable pharmacological properties.

In particular, by inhibition of the enzyme reversetranscriptase, the multiplication of retroviruses is
prevented, i~e. the compounds according to the present
invention possess especially cytostatic, as well as
antiviral properties.
The structural units of nucleic acids contain, as
glycosidic components, e-ther the ~-D-ribofuranosyl
radical or the 2-desoxy derivative thereof. Besides
these aglyconic radicals, modified D-ribofuranosyl
derivatives are also found in nucleoside antibiotics.
Thus, for example cordycepin, which can be isolated from
culture ~iltrates of ~ y~ militaris, contains the
monosaccharide cordycepose. Besides this 2'- or 3'-
desoxy derivatLve of the ribonucleosides, some consider-
able time ago, 2',3'-didesoxynucleosides have been
~- prepared synthetically. They have an anti-viral action
and can, in particular, via~the inhibi~ion of the enzyme
re~erse transcriptase~ inhibit ~he multiplication of
~ retroviruses (cf. Proc. ~atl. Acad. Sci. USA, 83, 1911/
;~ 20 1986 and Nature, 325, 773/1987). The inhibitory action
on the HIV virus 9 the cause of AIDS, is of especial
therapeutic interest. However, they have the disadvantage
~ :
that they are also inhibitors of cellular DNA polymerase
so that they act cytotoxically. Furthermore, they can
be deactivated by cellular enzymesO The compounds o
~ general formula I do not display these disadvantages.
- ~ They have an antiviral action without being cytotoxic.

2~ ~ ~
-12-
The compounds of general formula I according to
the present invention can also be ad~antageously used
for DNA sequencing according to Sanger's method. The
sequencing of d(G-C)-xich DNA fragments is, in particular~
made difficult by the formation of secondary struc~ures
which lead to a band compression in the region of d(G-C)
clusters. The reason for this is the Hoogs~een base
pairing of guanosine molecules. By means o the replace-
ment of 2'-desoxyguanosine triphosphate by the compounds
according to the present invention, in which R6 is a
hydroxyl group, the band compression is largely overcome.
The compounds of general formula I according to
the present invention, in which R6 and R7 are hydrogen
atoms, are used in DNA sequencing by Sanger's method as chain
tenNnators instead of the known 2',3'-didesoxy ~ounds.
Nucleic acids which, as structural components,
contain one or more compounds of general formula I, can
be prepared according to known processes (for example
as described in Nucleic Acids Research, 14(5), 2319 et
seq./l986). However, they also resul~, for example, in
the case of the DNA sequencing. If compounds of general
formula I, in which R6 is a hydroxyl group, are used as
s~ructural components, then a nucleic acid can contain
several such structural componen~s; if, as s~ructural
component, a compound of general formula I is used, in
which R~ is a hydrogen atom, then such a st~uctural
component can only be incorporated once, namely, on the

-13-
end of the chain. The nucleic acids according to the
present invention are made up of 2 to 1000 and prefer-
ably of 8 to 50 nucleotide structural components, nucleic
acids with 15 to 30 nucleotide struc~ural components
being especially pref~rred.
These nucleic acids can also be used as antiviral
agents. As so-called anti-sense nucleic acids~ these
nucleic acids hybridise with the ssDNA/RNA of the virus
and make difficult the transcription to the virus DNA.
Such nucleic acids can be used especially as agents
against AIDS since they are not decomposed or only
decomposed with difficulty by the cell's own restriction
enzymes.
For the preparation of pharmaceutical compositions,
the compounds of general formula I, the pharmacologically
compatible salts thereof or nucleic acids containing them
~:`
~ are mixed in known manner with appropriate pharmaceutical
-~ carrier substances, aroma, flavouring and colouring
materials and formed, for example, into tablets or
dragees or, with the addition of appropriate adjuvants,
are suspended or dissolved in water or an oil, for
example olive oil.
:~ '
-~'
.~
,:

2 ~ ~
,
- 14 -
It will be understood that the salts of
compounds (I), when used in pharmaceutical com-
positions will suitably be both pharmacologically
compatible and pharmaceutically acceptable, by
which is intended salts which have the required
characteristics to render them suitable for formu-
la-tion in pharmaceu-tical compositions for
administration to living bodies.
The compounds according -to the present invention
can be administered enterally or parenterally in liquid
or solid form. As injection medium i-t is preferred to
use water which contains the additives usual in the case
of injection solutions, such as stabilising agen-ts J
. ' ~
::.
;~
,.
,.
~ ,,
:,
: . ' ' `
:~

2 ~ ~
" .
- 15 -
solubilising agents and/or buffers.
Such additives include, for example, tartrate and
citrate buffers, ethanol, complex oxmers (such as
ethylenediamine-tetraacetic acid and the non-toxic salts
thereof1 and nigh molecular weight polymers (such as
liquid polyethylene oxide~ for viscosity regulation.
; Solid carrier materials include, for example, starch,
lactose, mannitol, methyl cellulose, talc, highly dis-
persed silicic acids, high molecular weight fatty acids
(such as stearic acid), gelatine, agar-agar, calcium
phosphate, magnes-um stearate, animal and vegetable fats
and solid high molecular weight polymers (such as poly-
ethylene glycols). Compositions suitable for oral
administration can, i~ desired, contain 1avouring and
sweetening agents.
- The compounds according to the present invention
are usually administered in an amount of from 1 to
~ ~ 100 mg. and prefexably of from 2 to 80 m~. per day and
; per kg. body weight. It is preferred to divide up the
daily dose into 2 to 5 administrations, in which case
each administration comprisas 1 or 2 tablets with a
content o~ active ma~erial of from 5 to lOOOmg. The
tablets can also be retarded, in which case the number
; of administrations per day can be reduced -to from 1 to
:~ ~
3. The active material con~ent o ~he re~arded tablets
` can~be rom 20 to 2000 mg. The active material can also
be administered by injection one to eight times per day
,
,
.

.2~
- 15a -
or by continuous infusion, in which case amounts of
from 500 to 4000 mg./day normally suffice.
The following Examples are given for the purpose
of illustrating the present invention:-
Example 1.
2-Amino-7-desaza-2',3'-didesoxy-9-~-D-ribofuranosyl-
purin-6-one
a) 2-~(4,4'-Dimethoxytriphenylmethyl)-amino]-7-desaza-
2'-desoxy-5'-0-(4,4'-dime_hoxytriphenylmethyl)-9-~-D-
ribofuranosylpurin-6-one.
1.0 g. (3.8 mMole) 7-desaza-2'-desoxyguanosine is
evaporated twice with dry pyridine a~d then suspended in
20 ml. pyridine. 4.0 g. (11.8 mMole) 4,4'-dimethoxy-
triphenylme~hyl chloride and 2.5 ml. ~14.6 mMole) Hunig
~; 15 base ~N-ethyldiisopropylamine) are added thereto and the
reaction mixture is stirred for 3 hours at ambient
temperature.
The reaction mixture is subsequently introduced
into 150 ml. of a 5% aqueous solution o sodium
bicarbonate and extracted twice with lS0 ml. amounts of
dichloromethane. The combined organic ex~racts are dried
~over anhydrous sodium sulphate, filtered and chromato-
;graphed on silica gel 60 H (column lO x 4 cm., dichloro-
methane/acetone 9:1 v/v). After evaporation of the main
zone, the residue is dissolved in a little dichlorornethane
and~added dropwise to a mixture of n-hexane/diethyl ether
1 v/v)0 After filtration, there are obtained 2.04 g.
;~
,,
., ~ . . . ,: . .

!2~
~16-
(61% of theory) of the desired colourless, amorphous
compound. TLC (silica gel 3 dichloromethane/acetone
(8:2 v/v): Rf = 0.7; UV (methanol: ~max ~ 272 9
283 nm (shoulder) ( = 18800, 16400).
lH-NMR ([~6]DMSO): ~ = 1.75 (m, 2'-Hb), 1.86 (m, 2'-Ha);
3.09 (m, 5'-H)9 3.79 (m, 4'-H), 4.10 (m, 3'-H)3 5.19
(d, 3'-OH, J = 4.3 Hz), 5.61 (pt, l'-H~ J ~ 6.5 Hz),
6.16 (d9 6-H, J = 3.5 Hz), 6.62 (d, 5-H, J = 3.5 Hz),
10.35 (s, NH).
Analysis for C53H50N408
calc.: C 73.07; H 5~79; N 6.43
found: 73.02; 5.98; 6.34
b) 2-~(4,4'-Dimethoxytriphenylmethyl)-amino]-7-desaza-
2'-desoxy-3'-0-phenoxythiocarbonyl-5'-0~(4,4'-dimethoxy-
triphenylmethyl)-9- ~ -one.
~` A suspension of 1.0 g. (1.1 mMole) of the compound
`~- of la) in 15 ml. dry acetonitrile is mixed with 300 mg.
~ (2.5 mMole) ~-dimethylaminopyridine and 300 ~1 ~2.2
`;~ mMole) phenoxythiocarbonyl chloride and stirred Eor 16
hours at ambien~ temperature. The reaction mixture is
evaporated and ~he residue chromatographed on a silica
gel 60 H column (column 10 x 4 cm., dichloromethane/
acetone; 8:2 vlv). The residue obtained by evaporation
; ~ o~ the main zone is dissolved in a little dichloromethane
and precipitated out by the dropwise addition of a
` ~ mixture o~ n-hexane/diethyl ether (1:1 vlv) to give
. ~ _
0.99 g. (39% of theory) of a colourless, amorphous
~'
.

substance. TLC (silica gel, methylene dichloride/
acetone (8:2 v/v): Rf = 0.8; UV (methanol): ~ max =
269, 282 nm (shoulder) (~ = 19300, 16000).
lH-NMR ([D6]DMS0): ~ = 2.06 (ml 2l-Hb) 9 2.34 (m, 2'-Ha),
S 3.26 (m, 5'-H), 4.25 (m, 4'-H), 5.61 (m, 3'~H and l'-H),
6.23 (d, 6-H, J = 3.5 Hz)~ 6.67 (d, 5-H, J = 3.5 Hz),
10.41 (s, NH).
Analysis for C60H54N4O9S (M~Wo 1007.2)
calc. : C 71.77, H 5.40, N 5.56, S 3.18
found: 71.26, 5.43, 5.52, 3.11
c) 2-[(4,4'-Dimetho~ytriphenylmethyl)-aminol~7-desaza-
2',3'-didesoxy-5'-0-(4,4'-dimethoxytriphenYlmethyl)-
9-~-D-ribofuranos~lpurin-6-one.
;~ 500 mg. (0.5 mMole~ of the compound of lb) in 20 ml.
freshly distilled toluene are mixed with 30 mg. (0.2
mMole) 2,2'-azo-bis-(2-methylpropionic acid nitrile) and
300 ~1~ ( l o l mMole) tributyl tin hydride and stirred for
3 hours under an atmosphere of argon at 80C. (TLC
monitoring, chloroform/methanol 97:3 v/v). After
completion of the reaction, the reaction mixture i9
evaporated and the residue chromatographed on silica gel
.
60 H (column 30 x 4 cm.; dichloromethane/methanol 99:1
vfv). After evaporation of the main zone and ~aking up
;~ in a llttle dichloromethane, 320 mg. (75% of theory) of
the desired amorphous, ~olourless compound is precipit-
~- ated out by dropping into n-hexane/diethyl e~her. TLC
(silica gel, methylene chloride/methanol~ 95:5 v/v~:
Rf . 0.5.

~L 3 ~
-18-
lH-NMR ~[D6]DMSO): ~ = 1.63, 1-80 (2 m, 2'-H and 3~-H),
3O07 (m, 5'-H), 4006 (m~ 4'-H), 5.43 (m, l'-H), 6.11
(d, 6-H, J = 3.5 Hz~, 6.65 (d, 5-H5 J = 3.5 Hz~9 10.34
(s, NH).
d~ 2-Amino-7-desaza-2',3'-didesoxy-9-~-D-ribofuranosyl-
purine-6-one.
300 mg. (0.35 mMole) of the compound from lc) are
dissolved in lO ml. 80% acetic acid and stirred for 15
minutes at ambient temperature. Subsequen~ly, the
solvent is stripped off at oil pump va-cuum and ~he
residue evaporated several times with wa~er. The crude
product is chromatographed on silica gel 60H ~column
10 x 4 cm., dichloromethane/methanol 9:1 v/v). The
foamy substance obtained by evaporation of the main
fraction ls crys~allised from a little methanol to give
50 mg. (57% of theory) of colourless needles; m.p.
- 228C. (decomp.). TLC (silica gel, dichloromethane/
methanol 9:1 v.v): Rf = 0.3.
~ UV (methanol): ~max = 2613 281 nm (shoulder~ (~ = 133009
;~ 20 7800).
H-NMR ([D6~DMSO): ~ = 1.96 ~m, 3'-H), 2.08, 2.27
(2 m, 2l-Ua and 2'-Hb), 3.48 (m, 5'-H)9 3.97 (m, 4'-H),
4086 (t, 5'-OH, J = 5.4 Hz)9 6.12 (pt~ l'-H, J = 5.5 Hz),
6.24 (m, NH2 and 6-H~, 6.92 (d9 5-H, J = 3.5 Hz), 10.34
(s, NH).
Analysis for CllHl~N4O3 (M.W. 250-3)
calc. . C 52.79, H 5.64, N 22.39
found : 52.98, 5.80, 22.55

-19-
In an analogous manner, via the corresponding 2'-
desoxynucleosides and subsequent deoxygenation as in c),
there are obtained the following compound6:
A) 3?7-didesaza-2',3'-didesogy-9-~-D-ribofuranosyl-
purine
UV (0.1 N HCl): ~ max = 224, 274 nm
Analysis for C12H14N202 (M.W. 218.2)
calcO : C 66.0, H 6.4, N 12.8
found : 66.1, 6.4, 12.6
B) 3,7-didesaza-2',3'-didesoxy-9-~-D-ribofuranosyl-
purin-6-one
) ~max = 264 nm ( = 11600), 282 nm ~ =
8000), 295 nm (~ = 5200)
~; Analysis for C12H14 2 3
calc. : C 61.5, H 6O0~ N 11.95
found : 61.3, 6.1, 11.8
C) 2-chloro-6-methoxy-3,7-didesaza-2',3'-didesoxy-9-~-
D-ribofuranosylPurine
.
UV (methanol): ~ max = 271, 280 nm
~alysis for C13Hl5N203Cl (M.W. 282.6)
calcO C 55.2, H 5.3, N 9.9
found : 55.1, 5.3, 9.9
D) 6-amino-3,7-d_desaza-2',3'-d des~-9-R-D-ribo~
furanosylpurine
Analysis for C12H15 3 2
calc. : C 63.65, X 6.16 N 17.13
found : 63~62, 6 11, 17.01
' `'

-20-
UV (methanol) ~max = 271 nm ( = 12800)
E) 3,7-didesaza-2',3'-didesoxy-9-~-D-ribofuranosylpurine-
.
2,6-dione
An~lysis for C12H1gN2OA ~M.W. 250.2)
calc. : C 57.55 H 5.6 N 11.2
found : 57.50 5~7 11.2
Example 2.
. _
2-~{[(Dimethylamino)-methylene]~amino~-7-desaza-2e,3'-
_ _ _ _ _ _
didesoxy-9-~-D-r _ofuranosyl~l-rin-6-one.
a) 2 [(Dimethylamino)-methylene]-a_ino-7 desaza-2'-
desoxy-9-!3-D-ribofuranosylpurin-6-one.
270 mg. (1.01 mMole) 7-desaza-2'-desoxyguanosine
in 5 ml. dry, amine-free dimethyl~ormamide are mixed with
2 ml. (11.7 mMole) N,N-dimethylormamide diethyl acetal
and stirred for 1 hour at 50C. under an a~mosphere o
` argon. Subsequen~ly9 the reaction mixture is evapora~ed
in a vacuum and the residue chromatographed on silica
gel 60 H (column 10 x 4 cmO ~ dichloromethane/methanol
9:1 v/v). By evaporation of the solvent, from ~he main
zone there are obtained 230 mg. (71% of theory) of a
pale yellow, amorphous substance. TLC (sillca gel,
dichloromethane/methanol 9:1 v/v): R~ = 0.3.
UV (methanol): ~max = 240, 311 nm (~ = 18300, 17400).
H~N~R ([D6lDMSO: ~ = 2.15 (m, 2'-Hb~, 2.41 (m, 2'~Ha),
3.02, 3.15 (s, 2 CH3), 3.52 (m, 5'-H)9 3O79 ~m9 4'~H),
4.32 (m, 3'-H), 4.91 (~, 5'-OH, J = 5.4 Hæ), 5.27
(d, 3'-O~d, J = 3.5 Hz~ 9 6.34 (d, 6-H, J = 3.5 Hz),

~ 3 ~
-21-
6.45 (pt, ll-H, J = 7.0 Hz)~ 7.Q7 (d; 5-H, J = 3.5 Hz),
8.56 (s, NH=C), 11.04 (s, NH).
Analysis for C14HlgN5O4 (M.W 321.3)
calc. : C 52.33, H 5.96, N 21.79
found : 52.48, 6.14, 21.69
b) 2-{E(Dimethylamino)-methylenel-amino}-7-desaza 2'-
desoxy-5'-0~(4,41-dimetho~ytriphenylmeth~l)-9-,B-D-
ribofuranosylpurin-6-one.
100 mg. (0.31 mMole) of the compound from 2a) are
~ 10 dissolved in 2 ml. dry pyridine, mixed with 170 mg.
`~ (0.5 mMole) 4,4'-dime~hoxytriphenylmethyl chloride and
0.2 ml. (1.2 mMole) Hunig base and stirred for 3 hours
at ambient temperature. Subsequently, the reaction
mixture is evaporated and the residue chromatographed
on silica gel 60 H (column 10 x 2.5 cm., elution agent
~:: chloroform/methanol 99:1 v/v). The residue obtained by
.
evaporation oE the main fractio~ is dissolved in
me~hylene chloride and, by dropping into a mixture of
: n-hexane/dîethyl ether (1:1 v/v), 160 mg. (84% of
theory) of a colourless, amorphous substance are
precipi~ated out. TLC (silica gel, me~hylene chloride/
methanol 9:1 v/v): R~ ~ 0.6.
~ ~ .
UV (methanol): ~ max = 2363 311 nm (~ - 38200, 18100).
H-NMR ([D6]DMSO): ~= 2.23 (m, 2~-Hb)~ 2.42 (m, 2'-Ha),
3~03 (s, CH3), 3.14 (m, 5'-H and CH3), 3.90 ~m, 4'-H),
:~;. 4.33 (m,~3'-H), 5.34 (d, 3'-OH, J = 4.3 Hz), 6.34 (d,
~ : 6-H, J = 3.5 Hz), 6~49 (pt, l'-H, J = 6.8 Hz), 6.90 (d,
- : :
: ~
. ~. .
-':
~ . ~, . .

2~ ~
~22-
5-H, J = 3.5 Hz), 8.58 (S9 NH=C)j 11.07 (s9 NH).
Analysis for C35H37N5O6 SM.W. 623~7)
calc. : C 67.40, H 5.98, N 11~23
found : 67.319 6.00, 11.17
c) Z-{[(Dime-thylamino) methylene]-amino}-7-desaza-2'-
desoxy-3'-0-phenoxythiocarbonyl-5' 0-(494'-dimethoxy-
triphenylmethyl)-9-~-D-ribofuranosylpurin-6-oneO
900 mgO (1.4 mMole) of the compound from 2b),
dissolved in 15 ml. dry dichloromethane, are mixed with
10 340 mg. (2.8 mMole) p-dimethylaminopyridine and 250 ~
(1.8 mMole) phenoxythiocarbonyl chloride and stirred for
16 hours at ambient temperature. The solution is evapor-
ated in a vacuum and the residue chromatographed on
silica gel 60 H (column 20 x 4 cm., chloroform/acetone
7:3 v/v). The residue obtained by evaporation of the
main zone is ~aken up in a little dichloromethane and
the desired colourless, amorphous compound precipitated
; out by dropping into n-hexane/diethyl sther (1:1 v/v).
TLC (silica gel, methylene chloride/me~hanol 95:5 v/v):
R = 0 5
~ ma~ = 235, 277 (shoulder), 283, 312 nm-
(~ = 41300, 11400, 12600, 17000).
H-NMR (~D6]DMS0): ~ = 2.73 ~m, 2'-Hb), 2.97 (m, 2'-Ha)9
3.01, 3.10 (s, 2 CH3), 3.37 (m, 5'-H), 4~33 (m, 4'-H),
25 5.90 (m, 3'-H), 6.40 (d, 6-H, J - 3.5 Hz), 6.55 (pt,
H), 6.98 (d, 5-H, J = 3.5 Hz), 8.58 (s, CH=N),
~ 30 (s, NH).
,; , `
,:

L 2 ~ ~L
-23-
Analysis for C42H41N5O7S (M.W. 759.9)
calc. : C 66.39, H 5.44, N 9.22, S 4.22
found : 66.49, 5.55, 9.25, 4.29
d) 2-~(Dimethylamino3-methylene]-amino}-7-desaza-
2',3' didesoxy-5'-0-(4,4'-dimethoxytriphenylmethylj-
. _
9-~-D-ribofuranosylpurin-6-one.
500 mg. ~0.7 mMole) of the compound Erom 2c),
dissolved in 20 ml. freshly distilled toluene, are mixed
with 25 mg. (0.15 mMole) 2,2'-azo-bis-(2-methylpropionic
acid nitrile) and 500 ~1. (1.9 mMole~ tributyl tin
hydride and stirred for 16 hours at 80C. under an
atmosphere of argo~. 5ubsequently, the reactlon mixture
is evaporated under oil pump vacuum and the residue
chromatographed on silica gel 60 H (column 20 x 4 cm.,
dichloromethane/acetone 9:1 v/v, chloroform/acetone 7:3
v/v, chloroform/acetone 6:4 v/v). The residue obtained
by evaporation of the main fraction is dissolved in a
little dichloromethane and precipi~ated out by dropping
into n-hexane/diethyl ether to give 320 mg. (80% of
theory) of the desired colourless~ amorphous compound.
TLC (silica gel~ methylene chloride/me~hanol 95:5 v/v):
R~ = 0.3.
~ max. = 236, 277 (shoulder3, 284 312 nm
( ~= 37200~ 12000, 13500, 1~000).
lH-NMR (~D6]DMSO): ~ = 2.02 (m, 3'-H), 2.20, 2.33 (m,
2'-Ha and 2'-Hb), 3.02~ 3.13 (s, 2 CH3), 3.08 (m, 5'-H),
4.17 (m, 4'-H), 6.31 (d, 6-H, J = 3.5 Hz), 6.38 (m, l'-H)p

2 ~ ~
-2~-
6.92 (d, 5-H, J = 3.5 Hz) 7 8.61 (s, CH=N), 11.03 (s, NH).
Analysis for C35H37N~G7 (~-W- 607-7)
calc. : C 69.18, H 6.143 N 11.52
found : 69.23, 6.24, 11.61
e) 2-{l(Dimethylam_no)-methylene] amino~-7-desaæa-
2',3'-didesoxy-9-!3-D-ribofuranosylpurin-6-one.
130 mg. (0.21 mMole) of the compound from 2d) are
dissolved in 80% acetic acid and stirred for 15 minutes
at ambient temperature~ Subsequently, the acetic acid
is evaporated off under oil pump vacuum and the residue
is chromatographed on silica gel 60 H (column 20 x 2 cm.,
,~ dichloromethane/methanol 95:5 v/v). The residue
obtained by evaporation of the main fraction is foamed
~ up by repeated evaporation with acetone to give 43 mg.
; 15 (67% of ~heory) o~ the, desired colourless, amorphous
compound. TLC ~silica gel, dichloromethane/methanol
9:1 v/v): R~ = 0.5. '
) max. = 239, 282 (shoulder), 311 nm
~' ( = 17400, 10500, 16900).
lH-NMR ([D6]DMSO): S = 2.06, 2.3~ (m, 2'-H and 3'-H),
3.01, 3.14 (s, 2 CH30~, 3.51 (m, 5'-H), 4.00 (m, 4'-H),
4.87 (t, 5'-OH~, 6.33 (m, l'-H and 6-H, J = 3~3 Hz),
7.05 (d, 5-H, J = 3.3 Hz), 8.59 (s, CH=N), 11.02 (s, NH).
; Analysis for C14HlgN5O3
calc. : C 55.07 9H 6.27,N 22.94
found : 55.23,6.41, 22.75
~:
,

-25-
Example 3.
2-Amino-6-methoxy-7-desaza-2',3'-didesoxy-9-~-D-
ribofuranosylpurineO
a) 2-Amino-6-methoxy-7-desaza-2' desoxy~
ribofuranosylpurine.
543 mg. (10 mMole) finely powdered potassium
hydroxide and 68 mg. (0.2 mMole) tetrabutylammonium
hydrogen sulphate in 30 ml. anhydrous dichloromethane
are stirred for 15 minutes at ambient tempera~ure under
an atmosphere of nitrogen. Subsequently, the reaction
mixture is mixed with 330 mg. (2 mMole) 2-amino-6-methoxy-
7-desazapurine (2-amino-4-me~hoxy-7H-pyrrolo[2,3-d]-
pyrimidine) and stirred for a further 30 minutes. After
the addition of 884 mg. (2.2 mMole) 2-desoxy-3,5-di-0-
~-toluoyl-~-D-erythro-pentofuranosyl chloride, stirring
is con~inued for a further 3 minutes. Insoluble compon- !
ents are filtered off with suc~ion, washed with a little
dichloromethane and the filtrate concentrated to about`
10 ml. Ater mixing with 3 ml. lM sodium methoxide in
methanol, stirring is continued for 3 hours at ambient
temperature. After neutralisation with acetic acid, the
solvent is stripped off, the residue is taken up in hot
water, filtered and ~he filtra~e chromatographed on an
exchanger column of Dowex*(l x 2 OH ~orm, 30 x 3 cm.)
(water/methanol 9:1 v/v). After stripping off the
~ solvent and recrystallising from water, from the main
; zone there are obtained 260 mg. (63% of theory) of
* Trade Mark
.
, ,' : : '

- ~3~ ~2~
-26-
colourless crystals; m.p. 152 - 154C. TLC (silica
gel, dichloromethane/methanol 9:1 v/v): Rf = 0.7.
UV (methanol): ~ max = 225, 259, 285 (~ = 24900, 36009
7600
lH-NMR ([D6]): S = 6~27 (lH9 d, J = 3.7 Hz), 6.42 (lH,
d~ Jl~,2~a ~-4 Hz~ Jl',2'b = 5 9 Hz), 7.10 (lH, d,
J = 3.7 Hz) ppm.
13C-NMR (~D6]DMSO):~ = 52.49 (OCH3), 82.37 (C-l'),
98.85 (C-5), 119~45 ~C-63 ppm.
b) The compound 2-amino-6-methoxy-7-desaza-2'-desoxy-
9-~-D-ribofuranosylpurine ob~ained according to a) is
desoxygenated in the manner described in Example lc) to
give 2-amino-6-methoxy-desaza-2',3'-didesoxy-9-~-D~
ribofuranosylpurine.
Example 4.
2-Amino-6-chloro-7-desaza-2',3'-didesoxy_9-~-D-
ribouranosyl~urine.
a) The compound is prepared, after acetylation of
2-amino-7-desaza-2',3'-didesoxy-9-~-D-ribofuranosylpurin-
6-one (prepared according to Example ld) by halogenation
according to the method described in Liebigs Ann. Chem.,
1987, 15 - 14~
bj The resulting crude mixture is~ for the removal of
the ace~yl protective group, left to stand or 3 hours
2$ in methanolic ammonia solu~ion at ambient temperature,
then evaporated to dryness and finally chromatographed
on silica gel with the elution agent chloroform/methanol.
~ .
~ ~ ' . ' '
.
,

-27-
After combining the main fractions and evaporating,
the residue obtained is crys~allised from water.
UV (methanol): ~ max = 235, 258, 316 t = 27800,
~300, 5800).
Analysis for CllH13N402Cl (M.W. 268.7)
calc. : C 49.1,H 4.8, N 20~8,Cl 13.0
ound : 49.3,4.85, 20.7, 13.1
Example 5.
2-Amino-7-desaza-2',3'-didesoxy-9-~-D-ribofuranosyl-
purine.
268 mg. (1 mMole) 2-amino-6-chloro-7-desaza-2',3'-
didesoxy 9-~-D-ribofuranosylpurine are dissolved i.n
25 ml. 70% aqueous methanol 7 added to a suspension o
30 mg. prehydrogenated Pd/C (10%) in 25 ml. 70% aqueous
methanol and hydrogenated until the take up of hydrogen
` is complete. The solvent is stripped of and the residue
is crystallised from methanol. Yield 180 m~O (77% of
theory).
Analysis for CllHl4N4O2
calc. : C S6.4, H 6.0, W 23.9
found : 56.3, 6.0, 23.7
UV (methanol): ~ ~ax = 234, 2563 314 nm (~ - 30600
41009 5200).
Example 6.
2-Amino-6-mercapto-7-desaza-2',37-didesoxy-9-~-D
ribofuranosy~purine.
53~ mg. (2 mMole~ 2-amino-6-chloro-7-desaza-2',3'-
;"
~, .
,

2 ~ ~
-28-
didesoxy-9-~-D-ribofuranosylpurine and 1.5 g. (20 mMole)
thiourea are suspended in 30 ml~ ethanol and heated
under reflux for about 15 hours. Thereafter, the
solvent is distilled off, the residue is taken up in
about 25 ml. methanol and then chromatographed on silica
gel 60 H (column 20 x 3 cm., dichloromethane/methanol
9:1 v/v). By evapo-ration of the main fraction and
crystallisation from methanol/water, there are obtained
2~0 mg. ~43% of theory) o~ the thio compound.
10 Analysis for CllH14N4O2S (M.W. 266.3)
calc. : C 49.6, H 5.3~ N 21.0
found : 49.4, 5.4, 21.1
UV (methanol): ~ max = 235, 271, 345 nm ( = 1760009
11700, 18700).
15 lH-NMR ([D6~DMSO)- ~ = 1.9 (~, 3'-H), 2.1 (m, 2'-Hb)~
2.34 (m, 2'-Ha), 3.50 (m, 5'-H), 3.97 (m, 4'-H), 4.86
(t, S'- OH), 6.12 (m, l'-H), 6.24 (m, NH2 and 8-H),
6.92 (d, 7-H), 11.1 (s, NH).
~- ' ' ;
20 2,6-Diamino-7-desaza-2',3'-didesoxy 9-~-D-ribo-
furanosylpurine.
26~ mg. (1 MMole) 2-amino-6-chloro-7-desaza-2',3'-
; didesoxy-9-~-D-ribofuranosylpurine are mixed with 40 ml.
- aqueous concentrated ar.lmonia solu~ion and heated for 60
hours at 65C. on a waterbath in a tightly clased vessel.
After evaporation of the solvent, the residue is
chromatographed on a silica gel column, first with
. .
. ., . ~ , .
' ~ .

~ 3 ~
-29-
dichloromethane/methanol (9:1 v/v) (starting material)
and then with chloroform/methanol (4:1 v/v). A~ter
crystallisation from water, there are obtained 120 mg.
(48% oE theory) of the desired diamino compound.
Analysis for CllH15N5O2 (M.W. 249~3)
calc. : C 53.0, H 6.0, N 28.1
found : 53.15, 5.9, 28.2
UV (methanol): ~ max = 264, 284 nm ( = 9800, 8000).
H-NMR ([D6]DMSO: ~ = 1.9 (mS 3'-H), 2.1, 2.4 (2 m,
2'-Ha b~ 3.4 (m, 5'-H), 3.8 (m, 4'-H)~ 4.8 (t, S'-OH),
5.6 (s, NH2), 6.2 (dd, l'-H), 6.3 (d, 7-H), 6.7 (s, NH2),
6.9 (d, 8-H~.
Example 8.
2-Methylthio-6-~e-th~-7-desaza-2',3'-didesoxy-9-~-
D-ribofuranosy~ e.
a) 2-Methylthio-6-methoxy-7-desaza-2'-desoxy ~9-~-D-
r~h~ IF~e L~-
500 mg. (2.56 mMole) 4-Methoxy-2-methylthio-7H-
pyrrolo~2,3-d]pyrimidine and 400 mg. (1.75 mMole)
benzyltriethylammonium chloride are dissolved in 20 ml.
; dichloromethane with 20 ml. of a 5% aqueous solution of
sodium hydroxide as counterphase and brie1y mixed up
in a vibratory mixer. 1.2 g. (3.1 mMole) 2-desoxy-3,5-
~; di 0-(~-toluoyl~-~-D-erythro-pentofuranosyl chloride
in a little dichloromethane, is added there~o and the
vibratory~mixing continued for 30 minutes. The organic
phase is separated o~f and the aqueous phase shaken up
.
' '`
"
~ .
, . . . . . . . . . .
~ ' ' ` , '
,
:

2 ~ ~
-30-
with dichloromethane. The combined organic extracts are
washed with water and dried with anhydrous sodium
sulphate. After filtration, the filtrate is evaporated
and the residue dissolved in 100 ml. lM sodium
methanolate in methanol. The solution is stirred for
about 12 hours at ambient temperature, then evaporated
and the residue is -taken up in water and adsorbed on a
Dowex l-X2 ion exchanger column (30 x 3 cm., OH form).
Elution with water-methanol (1:1 v/v) gives a main zone.
After evaporation of the solvent, the residue is re-
crystallised from water; yield 321 mg. (40% of theory)
of colourless needles; m.p. 118C. TLC (silica gel;
dichloromethane/acetone 8:2 v/v): R~ = 0.26.
UV (methanol): ~ ~ax ~ 283, 236 nm ( = 13000, 15500).
lH-NMR ([D~]DMSO): ~ = 2.20 (m, 2'-H), 2.40 (m, 2'-H),
2.56 (s, CH3S), 3.50 (m. 5'-H2), 3.81 (m, 4'-H), 4.01
(s, CH30), 4.35 (m, 3'-H), 4.90 (t, 5'-OH, J = 5 Hz)~
5.29 (d, 3'-OH, J = 4 Hz)~ 6.48 (d, 5-H, J = 4 Hz),
6.55 (t, l'-H, J = 5 Hz), 7.47 (d, 6-H, J = 4 Hz~.
Analysis for Cl3H17N3O4S (M.W. 311.4)
calc. : C 50.15, H 5.50, N 13.50, S 10.30
found : 50.2~9 5.47, 13.56, 10.31
b) 2-Me~lthio-6-methoxy-7-desaza-2',3'-didesoxy-9-
~3b~.
This is prepared by deoxygena~ion of the 2'-desoxy
` compound obtained according to a) in the manner des-
cribed ln Example lc~.

-` ~3~ ~ 2~1
-31-
UV Smethanol): ~ max = 283, 236 (~ = 1300, 15500)
Analysis for C13H17N3O3S (M.W. 295.4)
calc. : C 52.8, H 5.75, N 14.2
found : 52.6, 5.70, 14.2
Example 9.
6-Methoxy-7-desaza-2',3'-d _esoxy-9~~-D-ribofuranosyl-
a) 6-M~ xy-7-desaza-2'-desox~-9-~-D-ribofuranos~l-
purine.
The synthesis of this co~pound takes place in the
manner described in Liebigs Ann. Chem., 1985, 1360-1366.
b) The didesoxy derivative can be obtained by
deoxygenation of the compound obtained in a) in the
manner described in Example lc).
~, . .
An alternative way is the desulphurisation of 2-
methylthio-6-methoxy-7-desaza-2',3l-didesoxy-9-~-D-
ribofuranosylpurine from Example 8, also in the manner
described in LLebigs Ann. Ghem. 9 1985, 1360 - 1366.
TLC (dichloromethane/methanol 9:1 v/v~ Rf = 0.8.
UV (methanol): ~ max = 261 nm (log ( ) = 3.86).
H-NMR (DMSO-d6): ~ = 2.04 (m, 3'-H), 2.24 (m, 2'-}lb),
2.40 (m, 2'-Haj, 3.55 (m, 5'-H), 4.04 (s, ~CH3), 4.07
(m~ 4'-H), 4.93 ( t, J = 5.5 Hz, 5'-OH), 6.47 (dd, J =
4.4 and 6.8 Hz, l'-H), 6.55 (d, J -- 3.7 Hz, 5-H),
7766 (d, J = 3.7 Hz, 6-H), 8.42 (s, 2-H).
, ,
Analysis for C12H15N33 (M-W- 249
calc. : C 57.89H 6.0, N 16.8
-~ fuund : 57.8, 6.05, 16.65
,
,(, . ......

~3~ ~2~1
-32-
Another possibility for the preparation of this
compound is descxibed in Example 24i).
~.
7-Desaza-2',3'-didesoxy-9-~-D~ribofuranos~lpurin-6-one.
The preparation of this compound takes place via
the 2'-desoxy compound as described in Liebigs Ann.
Chem., 1985, 312-320 and subsequent deoxygena~ion as
described in Example lc).
UV ~methanol): ~ max = 2589 280 (shoulder) ~ = 9200,
6400?.
TLC (dichloromethane/methanol 9:1 v/v): Rf = 0.5.
;~ lH-N~R (DMS0-d6): ~ = 2.00 (m, 3'-H), 2.16 (m, 2'-Hb),
2.37 (m, 2'-Ha), 3.49 (dd7 J = 4.9 and 11.6 Hz, 5'~H),
3.58 (dd, J = 4.2 and 11.6 Hz, 5'-H), 4~05 (m, 4'-H),
6.33 (dd, J = 4.2 and 6.9 Hz, 1'-~), 6.50 (d, J = 3.5 Hz,
5-H), 7.36 (d, J = 3.5 Hz5 6-~), 7.90 (s, 2H).
AnalYSis for C11~13 3 3
calc. : C 56.1, H 5.5, N 1798
found : 56.0, 5.3, 18.0
~; 20 A further possibility for the preparation of this
compound is described in Example 24j~.
~ Example 11.
;~ 7-Desaza-2',3'-didesoxy-9-~-D-r bofuranosylpurine-
2,6-dione.
The syn~hesis of this compound -~akes place via the
2'-desoxy compound as described in Liebigs Ann. Chem.,
1985, 312-320 and subsequent deoxygenation as described
in Example lc).
;
..

3~ ~2~1
-33-
UV (phosphate buffer; pH 7-0)o ~ max = 251~ 280 ~m
~ 500, 7400)
Analysis for C11~13N3O4 (M.W. 251.4)
calc. : C 52.5, H 5.2, N 16.7
found : 52.3,5.1, 1605
xample 12.
2,6-Dimethoxy-7-desaza-2',3'-didesoxy-9-~-D-
ribouranosylpurine.
This derivative is synthesised by phase transer
glycosylation and subsequent deoxygenation as described
in Example lc).
UV (methanol): ~ ~ax ~ 257, 271 nm (~ = 7300, 7400)
Analysis for C13H17 3 4
calc. : C 55.859 H 6.1, N 15.0
found . 55.7, 6.1 15.1
; ` Example 13.
6-Amino-7-desaza-2',3'-didesoxy~-~~D-ribo ura~y
~' ` urin-2-one.
This compound is ob~ained according to J. Chem.
20 Soc., Perkin Trans. II, 1986, 525 - 530 by phase transfer
glycosylation of 2-methoxy-6-amino-7-desazapurine,
subsequent deme~hylation and finally deoxygenation
~- ~ analogously to Example lc).
UV (methanol): ~ max = 255, 305 nm ~ = 7600, 7200)
25 Analys iS 11 14 4 3
- calc. : C 52.7, H 5.6, N 22r4
~ound : 52.75~ 5~5, 22.3
:

-34-
Example 14.
2-Amino-7-desaza-7-methyl-2',3'-didesoxY-9-~-D-
ribofuranosylpurin-6-one.
This compound is synthesised via the 2'-desoxy-
nucleoside described in Liebigs Ann. Chem., 1984, 708-
721 with subsequent deoxygena~ion as described in
Example lc).
) ~ max. = 224, 264, 285 nm (shoulder)
(~ = 22500, 10500, 6500)
Analysis for C12H16N403 (M.W. 264.3)
calc. : C 54.5, H 6.05, N 21.2
found : 54.3, 6.1, 21.1
Example_15.
2-Amino-7-desaza-2',3'-didesoxY-3'-azido-9-~-D-
ribofuranosylpurin-6-one.
.
This compound is prepared by glycosyla~ion of 2-
amino-7-desazapurin-6-one with the azido sugar prepared
according to Byatkina/Azhayev (Synthesis, 1984, 961-963).
UV (methanol): ~ max = 261, 281 nm (shoulder)
~ 20 (~ = 13300, 7800).
`~ Analysis for GllH13N73 (M.W. 291-3)
calc. : C 45.3, H 4.45, N 33.65
~ound : 45.4, 4-3~ 33-4
Example 16.
;~ furanosylpu_ine.
~ This compound is prepared by ribosidation of 3,7-
':'

2 ~ ~
didesazapurine wi~h the azido sugar prepared according
to Byatkina/Azhayev (Synthesis, 1984, 961-963).
UV (methanol): ~ma~ = 224; 274 nm.
Analysis for C12H13N502
calc~ : C 55.55, H 5.0 9 N 27.0
found : 55.4, 5.1, 26.8
Example 17.
6-Amino-8-aza-7-desaza-2',3'=didesoxy-9-~-D-ribo-
furanosylpuri_e (4-amino-1-(2-desoxy-~-D-erythro~
; lO pentofuranosyl)-lH-pyrazolo[3,4-d]pyrimidine)
a) 4-Benzoylamino~ 2'-desoxy-9-~-D-erY~hro-pento=
furanosyl-5'-0-(4,4'-dimethoxytriphenylmethyl)-lH-
pyrazolo~3,4-d]~yrimidine.
`~ 6-Amino-8-aza-7-desaza-2'-desoxy-~-D-ribo-
furanosylpurLne is prepared in the manner deseribed in
Helv. Chim. Acta, 68, 563 - 570/1985. The benzoylation
of the 4-amino group and the subsequent intxoduction of
the dimethoxytrityl protec~ive group is carried ou~
analogously to known methods.
b) 4-Benzoylamino-1-(2'-desoxy-~-D-erythro-pento-
furanosyl)-5'-0-(4,4'-dimethoxytriphenylmethyl)-
3'-0-phenoxy~hiocarbo~yl-lH-pyrazolo~3,4-d]-
pYrimidine.
200 mg. (0.3 mMole) of the product of Example 17a)
:
are reac~ed in 4 ml. acetonitrile with 82 ~1. (0.6 mMole)
phenyl chlorothiocarbonate at ambient ~emperature for
16 hours in the presence of 90 mg. (0.75 mMole) 4-
'~
::
~,~.,."

~3~! ~2~
-36-
(dimethylamino)-pyridine. After chromatographic
purification (silica gel, dichloromethane/ethyl acetate
95:5 v/v), there are isolated 150 mg. (63% of ~heory)
of the de~ired product.
TLC (silica gel 9 dichloromethane/ethyl acetate, 95~5
v/v: R~ = 0.4.
H-NI~R ([D6]DMSO): ~ = 3.26 (mS 5'-H), 3.69 (s, 2 x OCH3),
4.45 (m, 4'-H), 5.98 (m, 3'-H), 8.45 (s, 3-H)3 8.78
(s, 6-H)7 11.72 (s~ NH).
10 c) 4-BenzQylamino-1-(2',3'-didesoxy-9-~-D-glycero-
pentofuranosyl)-5'-0 _(4,4'-dimethoxytriphenYlmethYl)-
lH-pyrazolo[3,4-d]pyrimidine.
200 mg. (0.25 mMole) of the product of Example 17b)
are deoxygenated according to Barton's method in 7 ml.
15 toluene with 150 ~1. (0.55 mMole) tri-N-butyl stannane
at 80C. under an a~mosphere of argon. After chromato-
graphy (silica gel, dichlorome~hane/ethyl acetate 95:5
,~ .
v/v), there are obtained 120 mg. (75% of theory) of the
:
;~ desired colourless and amorphous product.
TLC (silica gel, dichloromethane/ethyl acetate 95:5 v/v):
Rf = 0.3
H-NMR ([D6]DMSO): ~ = 2.16 (m, 3'-H), 2.49 (m, 2'-H),
2.99 (m, 5'-H), 3.65, 3.68 (2s, 2 x OCH3)9 4.32 (m,
4'-H), 6.69 (m, l'-H), 8.41 (s, 3-H), 8.80 (s, 6-H),
11.66 (s, NH).
d) 6~Amino-8-aza-7-desaza-2',3'-didesoxY-9-~-D-ribo-
fur_nosyleurine (4-amino-1-(2'~3'-didesoxy-~-D
glyceropentofuranosyl)-lH-pyrazolo~3,4-d]pyrimidine)
'
~''' , . ' ' :
:

-37-
a) 300 mg. (0.47 mMole) of th~ product of Example 17c)
are treated in 40 ml. ammonia-saturated methanol at
60C. for 4 hours and then evaporated to dxyness. There
are obtained 200 mg. (81% of theory) 4-amino-1-(2',3'-
didesoxy-~-~-glyceropentofuranosyl)-5'~0-(4,4'-
dimethoxy-triphenylmethyl) lH-pyrazolo~394-d]pyrimidine
in the form of a colourless foam after chromatography
on silica gel (dichloromethane/acetone 7~3 v/v).
TLC (silica gel, dichloromethane/acetone 8:2 v/v):
Rf = O. 25~
H-NMR ([D6~DMSO): ~= 2.16 (m, 3'-H), 2~45 (~ 2'-H~,
2.99 (m, 5'-H), 3.69, 3.70 (2s, 2 x OCH3)~ 4.25 (m, 4'-H),
6~52 (m, l'-H), 7.74 (s, NH2)~ 8.06 ts, 3-H), 8.24
`~ (s) 6~H).
b) 110 mg. (0.2 mMole) of the above product are
stirred for 20 minutes at ambient temperature in 10 ml.
80% acetic acid. After chromatography (silica gel,
~; dichloromethane/methanol 9:1 v/v), there is obtained the
~ desired product in crystalline form. Subs~quent re-
;~ 20 crystallisa~ion from isopropanol/cyclohexane gives 40 mg.
(85~/o of theory) of the desired product as a colourless
~ solid.
; UV (methanol): ~max ~ 260~ 275 nm ( ~ = 9000~ 10200)~
AnalySis for C10~13~52
calc. : C 51.06,H 5.57,N 29~77
found : 50.96,5.65, 29.80
' ;
' :

3~2~L
-3~-
3C-NMR ([D6]DMSO): ~ = 133 (C-8), 100.3 (C-5), 158.1
(C-6), 156.1 (C-2~, 153~6 (C-4), 84.4 (C-l'), 30.4
(C-2'), 27.4 (C-3'), 81.7 (C-4'), 64.3 (C-5').
TLC (silica gel, dichloromethane/methanol 9:1 v/v):
Rf = 0.4.
UV (methanol): ~max = 260, 275 nm (~-= 9000~ 10200 ).
lH-NMR ([D6]DMSO): ~ = 2.11 (m, 3'-H), 2~40 (m, 2'-H),
3.36 (m, l'-X), 4.0~ (m, 4'-~), 4.75 (m, 5'-OH), 6.45
(m, l'-H), 7.75 (s, NH2), 8.14 (s, 3-H), 8.18 ~s, 6-H).
Example 18.
a) 4,6-Dichloro-1-(2'-desoxy-3',5'-di 0-p-toluoyl-~-
D-~rythro-pentofuranosyl)-lH-pyrrolo[3,2-c]pyridine.
A solution of 300 mg. (1.6 mMole) 4,6-dichloro-lH-
pyrrolo~3,2-c]pyridine in 75 ml~ dry acetonitrile, which
~- 15 contains 450 mg. (8.0 mMole) potassium hydroxide and
30 mg. (0.1 mMole) tris-[2-(2-methoxyethoxy~-ethyl]-
amine, is stirred at ambient temperature for 30 minutes
under an atmosphere of nitrogen~ Whilé stirring, 625 mg.
- ~1.6 mMole) a-chloro-2-desoxy-3,5-di-0-~-toluoyl-D-
erythro-pentofuranose ar~ added there~o and stirring
continued for 15 minutes. Insoluble material is then
filtered off and ~he filtra~e is evaporated in a vacuum.
The oily residue is chroma~ographed on silica gel
(column 17 x 4 cm., elu~ion agent dichloromethane/e~hyl
acetate 97:3 v/v). There are obtained 762 mg. (90% of
~heory) o$ ~he colourless, amorphous product.
H-NMR (Me2SO-d6j: ~ = 2.37 and 2.41 (2s, 2 CH3), 2.77
' ~ . ' ''' '

-39-
(m, H-2's), 2.94 ~m, H-2'), 4.57 (m, H-41, H-5'), 5.68
(m9 H-3'), 6066 (pt, H-l'), 6.71 (d, J = 3.5 Hz, H-3),
8.00 (s, H-7).
C-N~R (Me2SO-d6): ~ = 36.8 (C-2')~ 64.2 ~C-5'), 74.9
(C-3'), 81.7 (C-1')9 85.6 (C-4'), 102.0 (C-3), 106.1
(C-7) 9 123.1 (C-3a), 129.7 (C-2), 140.0 (C-6), 140.6
(C-4), 142.4 (C-7a).
b) 4,6-Dichloro-1-(2'-desoxy-~-D-erYthro-~e~nto-
furanosyl ? - lH-pyrrolo[3,2-c]pyridine.
500 mg. (0.93 mMole) of the compound of Example
18a) are dissolved in 30 ml. me~hanolic ammonia and
stirred for 12 hours at 50C. The solu~ion is evaporated
to dryness, the solid residue is adsorbed in silica gel
60 H (2 g.) and applied to a silica gel column (14 x 4 crn.9
elution agent chloroform/rnethanol 9:1 v/v). From the
main fraction there is isolated the desired produet in
the form of a colourless oil which crystallises roM
,
aqueous ethanol in the forrn of colourless needles.
Yield 101 rng. (72% of theory); mOp. 180C.
lH-NMR (Me25O-d6): ~ = 2.28 (m, H-2's), 2.43 (rn, H-2'a),
; 3~56 Im, H-5'), 3.85 (m, H-4'), 4.38 (m9 H-3'), 5O02
(t, J = 5.2 Hz, 5'-oHj, 5.34 (d, J = 4.1 Hz9 3'-OH),
6.42 (pt, ~-1'), 6.67 (d, J = 3.4 Hz, H-3)9 7~89 (d,
J = 3~4 Hz, H 2~, 7.96 (s, H-7)o
13C-NMR (Me2SO-d6): ~ = 40.6 (C-2'), 61.5 (C-51), 70.5
(C-3'), ~5~5 ~C-l'), 87.6 (C-4'), 101.3 (C~3) 9 106.1
(C-7)~ 123.1 (C-3a), 129.7 (C-2), 139.7 (C-6), 140.4
(C-4), 142.0 (C-7a)~
~'' . ~ .
,

-40-
c) 4 Amino-6-chloro-1-(2'-desoxy~-D-erythro-pento-
furan~y~ _l -p~_rolo[3 7 2-c]pYridine.
460 mg. (1.52 rnMole) of the compound of Example
18b) are dissolved in 6 ml. dry hydrazine and heated to
80C. for 60 minutes. The hydrazine is removed under a
vacuum and the oily residue evaporated twice with, in
each case, 10 ml. ethanol. The residue is dissolved in
40 ml. aqueous ethanol and ~hen 2 g. Raney nickel are
added thereto and the mixture heated to the boil for 2
hours, while stirring. The catalyst is filtered off and
thoroughly washed with hot aqueous ethanol. The filtrate
is evaporated to dryness, the residue is dissolved in
methanol, adsorbed on 2 g. silica gel and the solvent
removed under a vacuum. This silica gel is suspended in
chloroform/methanol (9:1 v/v) and applied to a silica
gel column (6 x 3 cm.). Elution with chloroform/
methanol (9:1 v/v~ gives a colourless syrup from which,
by crystallisation from methanol, the product can be
obtained in the form of small, colourless crystals;
m.p. 232C. Yield: 207 g. (48% of theory).
TLC (chloroform/methanol 9:1 viv): Rf = 0.2.
UV (methanol)- ~ max = 277 nm ( = 14800 ), 285 nm
( = 13800).
H-NMR (Me2SO-d6): ~ = 2.20 (m, H-2'm), 2.40 (m, H-2'a),
3.51 (m, H-5'), 3.78 (m, H-4'~, 4.32 (m, H-3'), 4.89
(t, J = 5 Hz, S'-OH) 9 5.26 (d, J = 4 Hz, 3'-OH), 6.19
- (pt, H-l'), 6.S5 (s, NH2), 6.64 (d~ J = 3 Hz, H-3)9
6.83 (s, H-7), 7,36 (d, J = 3 Hz, H-2).
.

-41-
3C-NMR (Me2SO-d6): ~ = 40 (C-2 ), 61-8 (C~5 ), 70.
(C-3'), 84.7 (C-l') 9 87.2 (C-4'), 95.1 (C-7), 101.6
(C-3), 109.6 (C-3a~, 123.5 (C-2), 141.0 (C-6), 141.4
(C-7a), 152.9 (C-4).
Analysis for C12H14ClN303
calc. : C 50.80, H 4.97, N 14.81, Cl 12.50
found : 50.91, 5.05, 14.75, 12.53
d) 4-Amino-1-(2'-desoxy-~-D-erythro-pentofuranosyl)-
yrrolo[3,2-c]~yridine.
A solution of 200 mg. (0.7 mMole) of the compound
from Example 18c) in 30 ml. methanol, which contains
0.4 ml. o~ ammonia-saturated methanol, is hydrogenated
in the presence of palladium/charcoal (50 mg., 10% Pd)
at ambient temperature for 30 hours. The catalyst is
fil~ered off and the solven~ removed in a vacuum.
Puri~ication by flash chromatography (column 4 x 4 cm.
elution agent chloroform/methanol/triethylamine 7:3:2
v/v/v) and crystallisation ~roM r~ethanol gives 70 mg.
(40% of ~heory) o~ the desired product in the form of
colourless crystals; m.p. 205C.
TLC (elution agent chloroform/methanol/triethylamine
7:3:2 vlv/v): Rf = 0.4.
UV (methanol):~rnax. 27
H-NMR (Me2SO-d6): ~ = 2.20 (rn, H-2'b), 2.42 ~m, H-2'a),
3.51 (m, H-5'), 3.80 (m, H-4'), 4.32 (m, H-3'~, 4.91
(m, 5'-OH), 5.32 (m, 3'-OH), 6.08 (s, NH2), 6.23 (pt,
H-1'), 6.65 (d, J = 3 Hz, H-3), 6.75 (d, J = 6 Hz, H-7~,

~` 42 ~3~
7.35 (d, J = 3 Hz, H-2), 7.55 (d, J = 6 Hz, H-6).
-N~ (Me2SO-d6): ~ = 39.8 (C-2'), 62.0 (C-5'), 70.8
(C-3'), ~4.5 (C-l'), 87.1 (C-4'), 96.9 (C-7), 101.5
(C-3), 11007 (C-3a), 122.5 (C-2), 13g.7 (C-6), 140.0
(G-7a), 153.7 (C-4).
AnalySis for cl2Hl5N3o3
calc. : C 57.82, H 6.07, N 16.86
found : 57.97,6.129 16.74
Example 19.
a) 6-Chloro-1-(2'-desoxy-~-D-erytnro-pentofuranosyl)-
lH-pyrrolo[3,2-c]pyridin-4-one.
A solution of 400 rng. (1.32 mMole) of the compound
of Example 18b) is heated to the boil ~or 30 hours in 2N
aqueous sodium hydroxide solution with a small amount of
1,4-dioxan. The reaction mixture is neutralised with 2N
hydrochloric acid, ~iltered and then applied to an
Amberlite*XAD 4 column (17 x 2 cm.). Inorganic salts
are removed by washing with water and then the produc~
is eluted with me~hanol. Crystallisation from wa~e~
;~ 20 gives 158 mg. (42% of theory) of colourless crystals;
m.p. 242 - 243C.
TLC (chlorofor~tmethanol 8:2 v/v): Rf = 0.5.
UV (methanol ? ~ max ~ 270 nm (~ = 11100), 292 nm
( - 9300).
lH-NMR (Me2SO-d6): ~ = 2.22 (m, H-2'b), 2.38 (m, H-2'a),
3.53 (m7 H-5'), 3.80 (m, H 4'), 4.33 (m, H-3'), 4.96
(m, 5'-OH), 5.29 (m9 3'-OH), 6.22 (pt9 H-l'), 6.54 (d,
~ Trade Mark

-43- -
J = 3.3 Hz, H-3), 6.96 (s, H-7), 7.38 (d, J = 3.3 Hz,
H-2), 11.81 (br. NH)o
3C-NMR (Me2SO-d6): ~ = 40.5 (C-2'), 61.7 (C-5'),
70.6 (C-3'), ~5.0 (C-l'), 87.4 (C-4'), 94.g (C-7),
104.1 (C-3), 114.0 (C-3a), 123.2 (C-2)~ 129.1 (C-6),
139.2 (C-7a), 158.7 (C-4).
Analysis for C12H13ClN2O4
calc. : C 50.63, H 4.60, N 9.84, Cl 12.45
found : 50.79, 4.74, 9.80, 12.69
10 b) 1-(2'-Deso~y-~-D-erythro-pentofuranosyl)-lH-
pyrrolo[3,2-c~pyridin-4-one.
A solution of 100 mg. (0.35 mMole) of the compound
of Example 19a) in 15 ml. methanol is mixed with 0.5 ml.
2~% aqueous ammonia solution and hydrogenated in the
presence of palladium/animal charcoal (10% Pd, 15 mg.)
for 3 hours at ambient tempera~ure. The catalyst is
filtered off and the filtrate evapora~ed to dryness.
The solid residue is crystallised frorn water. There are
obtained 51 mg. (58% of theory) of the desired product,
m.p. 147 - 148C.
~ TLC (elution agent chloroform/methanol 8:2 v/v):
; R = 0 3-
f
UV (met'nanol) ~ max = 264 nrn ( = 11700), 282 nm (sh,
= 8000)~ 295 nm (sh, = 5100).
lH-NMR (Me2SO-d6): ~ = 2.22 (m; H-2's), 2.40 (m, H-2's),
3.52 (m, H-5'), 3.81 ~m, H-4')~ 4.32 (m~ H-3'), 4.93
(t, J - 5.4 Hz, 5'-OH), 5.32 (d~ H - 4.3 Hz, 3'-OH),

-44-
6.21 (pt, H-l'), 6.54 (d, J = 3 Hz, H-3), 6.62 (d,
J = 7 Hz, H~7)~ 7.03 (d, J = 7 Hz9 H-6), 7.34 {d, J =
3 llz, H-2); 10.87 (br NH).
13C-NMR (Me2SO-d6): ~ = 40 (C-2'~ superimposed by solvent
signals), 61.8 (C-5'), 70.7 (C-3'), 84.8 (C-l'), 87.4
(C-4'), 93.8 (C-7)~ 104.6 (C~3~, 115.9 (C-3a), 122.0
(C-2), 127.8 (C-6), 139.0 (C 7a), 15~.6 (C-4).
AnalySis for C13~14N24
calc. : C 59.08, ~ 6.10, N 10.60
found : 59.09, 6.07, 10.65
Example 20.
a) 1-(2' De~ y ~-D-grythro-pentofuranosyl)-4~6-
dichloro-5'-0-(434'-dimethoxytrityl)-lH-pyrrolo-
5~0 mg. (1.65 mMole) of the compound of Example
18b) are evaporated ~o dryness wi~h 10 ml. pyridine.
The material is dissolved in 10 ml. dry pyridine and
0.7 ml. (4.1 mMole) of Hunig's bases, as well as
690 mg. (2.0 mMole) 4,4'-dimethoxytrityl chloride, added
thereto. The solution is stirred for 1 hour at ambient
temperature. After the addi~ion of 75 ml. of 5% aqueous
sodium bicarbnnate solution, it is extracted twice with,
in each case, 75 ml. dichloromethane. The combined
organic phases are dried over aTIhydrous sodium sulphate.
The sodium sulphate is filtered off and the filtrate
evaporated. The residue is applied to a silica gel
column (30 x 3 cm.; elution agent dichlorome~hane/
'.

11 $ ~
acetone 99:1 v/v). The product is obtained from ~he main
fraction in the form of a yellowish amorphous mass. The
product is dissolved in diethyl ether and precipitated
out with n-hexane. Yield 740 mg. (74% of theory).
lH-NMR (Me2SO-d6): ~ = 2.39 (m, H-2'b~/ 2.64 (m, H-2'a)~
3.09 (m, H-5'), 3.72 (s, 2 OCH3), 3.96 (m, H-4'), 4.42
(m, H-3'), 5.41 (d, J = 4.8 Hz, 3'-OH), 6.47 (pt, H-l'),
6.65 (d, J = 3.5 Hz, H-3), 6.76 - 7.27 (aromat. H)~ 7.76
(ds J = 3.5 Hz, H-2), 7.89 (s, H-7).
l3C-NMR (Me2SO-d6): ~ = 40 ~C-2' superimposed by solvent
signals), 55.1 (2 OCH3), 63.6 (C-5'), 70.05 (C-3'), 85.0
85.5. 85.5 (C-l', C-4', OCDMT)g 101.3 (C-3), 106.2 (C-7),
123.2 (C-3a), 129.1 (C-2), 139.8 (C~6), 140.5 (C-4) 7
142.3 (C-7a).
Analysis for C33H30C12N205
cale. : C 65.46, H 4.99, Cl 11.71,N 4.63
found : 6S.47, 5.09, 11.78, 4.56
b) ~
dichloro-5'-0-(4,4'-dimethoxytri~yl)-3'-0-phenoxy-0 thiocarbonyl-lH-~yrrolo[3,2-c]pyridine.
300 mg. (0.5 ~Mole) of the compound of Example 20a)
are dissolved in ll ml. dry acetonitrile and 350 mg.
(2.8 mMole~ 4-dimethylaminopyridine and 150 ~1. (1.1
mMole) phenyl chlorothiocarbonate added thereto and the
solution is stirred for 16 hours at ambien~ temperature.
The reaction mixture is subsequently evaporated ~o dry-
ness in a vacuum. The residue is chromatographed on

J~
-46-
silica gel (elution agent dichloromethane). The
colourless product is isolated from the main fraction.
Yield 310 mg. ( 84% of theory).
H-NMR (Me2SO-d6): ~ = 2.92 (m, H-2'a,b), 3.35 (m9 H-5'),
3.72 (s, 2 OCH3), 4.43 (m, H-4'3 9 5.89 (m9 H-3'), 6.61
(pt, H-l'), 6.71 (d, J = 3.5 Hz~ H-3), 6.81 - 7.52
(aromat. H), 7~76 (d, J = 3.5 Hz, H-2), 8.01 (s, H-7).
3C-NMR (Me2SO~d6): ~ = 37.0 (C-2'), 55.1 (2 OCH3), 63.8
(C-5'), 83.0, 84.2, 85.6~ 86.0 (C-l', C-3', C-4', OCDMT),
101.8 (C-3), 106.3 (C-7), 123.1 (C-3a), 128.9 (C-2),
140.1 (C-6)~ 140.6 (C-4), 142.4 (C~7a), 193.8 (C S).
Analysis for C40H3L~ 12 2 6
calc. : C 64.78, H 4.62, Cl 9.55, N 3.77, S 4.32
found : 64.66, 4.59, 9.65, 3.70, 4.40
c) 4,6-Dichloro-1-(2',3'-d desoxy~-D-glyceropen~o-
furanosyl)-5'-0-(4,4'-dime~hoxytrityl)-lH-pyrrolo-
[3,2-c]pyridine.
170 mg. (0.23 mMole) o the compound of Example
20 b) and 15 mg. (0.1 mMole) 2,2'-azo-bis-~2-methyl)-
propionitrile are dissolved in, 10 ml. dry toluene under
an atmosphere~of argon~ 140 ~1. (0.51 mMole) ~ri-n-butyl
stannane are~added thereto, while s~lrring, and the
reaction mixtùre is then further stirred for 3 hours at
80C. The solvent is removed under a vacuum and the
residue chromatographed on silica gel (elutlon agent
dichloromethane). From the main fraction are isola~ed
115 mg. (85% of theory) of the desired product.
. .
.
~ . .

--~7-
lH-NMR (Me2S0-d6): ~ = 2.05 ~H-3'), 2.50 (H-2', super-
imposed by signals of the solvent), 2.90 - 3.15 (m,
H-5'), 4.25 (m, H-4')9 6.38 (m, H-l'), 6.63 (d, J =
3O4 Hz, H-3), 6~69 - 7.30 (aromat. H), 7.79 (d, J =
3.4 Hz, H-2), 7.89 (s, H-7).
d3 2,6-Dichloro-3,7-didesaza-2' 9 3'-didesoxy-9-~-D-
rib_furanosylpu ine.
The dimethoxytri~yl protective group is removed
from the compound of Example 20c) analogously to Example
24f).
; e) 6-Amino-3,7-didesaza-2',3'-didesoxy-9-~-D-
ribofuranosylpurine.
The compound of Example 20d) is treated with
hydrazine and subsequently reduced with Raney nickel in
the manner described in Example 18c). There is thus
obtained the compound described in Example llD).
f) 3,7-Didesaza-2',3'-didesoxy-9-~-D-~ibofuranosyl-
purine.
The compound of Example 20d) is hydrogenated in
the pxesence of palladium/animal charcoal/hydrogen
analogously to Example 24g). There is obtained the
compound already described in Example lA).
g) 3,7-Didesaza-2',3'-didesox~-9-~-D ribofuranosYl-
:
purin-6-one.
The compound of Example 20d~ is ~reated with an
aqueous solution of sodium hydroxide in the manner
described in Example l9a) and subsequently hydrogenated
~ .
,
..
.

2 ~ ~
-48-
in the manner described in Example l9b). There is thus
obtained the compound already described in Example lE).
Example 21.
2-Amino-(2',3'-didesoxy-~-D-~lYceropentofuranosYl)-
lH-pyrazolo[3,4-d]pyrimidin-4-one.
This compound is prepared analogously to the method
described in Example 17 via 2-amino-(2'-desoxy-9-~-D-
ribofuranosyl)-lH-pyrazolo[3,4-d]pyrimidin-4-one and
Barton deoxygenation of 2-amino-(2'-desoxy-3'-0-methoxy-
thiocarbonyl-5'-tolUoylribofuranosyl)-lH-pyrazolo-
~3,4-d]pyrimidin-4-one; m.p. 221C.
Analysis Eor CloH13~503 (M.W. 251.25)
calc. : C 47.81, H 5.22, N 27.88
found : 48.01, 5.30, 27.83
13C-NMR (DMSO-d6): S = 135.1 (C-3), 99.7 (C-3a), 157.9
(C-4), 155.3 (C-6), 154.5 (C-7a), 83.8 (C-l'), 30.3
~C-2'), 27.3 (C-3'), 81.6 (C-4'), 64.3 (C-5').
H-NL~R: ~ = 6.19 (dd, l'-H, J = 6.9, 3.5 Hz), 2.06
(m~ 3'-H).
Example 22.
3~7-Didesaza-2'-desoxy-9-~-D-ribofuranosylpurine
(2'-desoxy-3,7-didesazanebularin)
The compound of Example 18b) is hydrogenated in
the presence of palladium/animal charcoal (10% Pd) in
ammoniacal methanol. After fil~ering off ~he catalyst
and evaporating the fil~rate in a vacuum, the product
is purified fror,l inorganic salts by chromatography on

.
-49-
Amberlite XAD (methanol/water)~ as well as by crystall-
isation from water; m.p. 175 - 176C.
UV (0.lm aqueous hydrochloric acid): ~ max ~ 224,
274 nm
13C NMR ([D6]DMSO): ~ = 126.9 (C-2), 101.7 (C-3~, 125.5
(C-3a), 143.3 (C-4), 140.6 (C-6)~ 105.9 (C-7), 139.2
(C-7a), 84.6 (C-l'~, 70.8 (C-3'), 87.8 (C-4')~ 61.9
(C~S').
lH-NMR (DMSO-d6): ~ = 2.23 (m, 2'-Hb), 2.29 ~m, 2'-I-Ia),
3 55 (m, 5'-H2), 3.85 (m, 4'-H), 4.38 (m, 3'-H), 4.99
(5'-OH), 5.37 (3'-OH), 6.42 (pt, l'-H), 6.66 (d, J =
3 Uz, 3H), 7~62 ~d, J = 6 Hz, 7-H), 7.71 (d, J = 3 Hz,
2-H), 8.21 (d, J = 6 Hz, 6-H), 8.23 (s, 4-H).
Analysis for C12Hl4N2O3
calc. : C 61~53, H 6.02~ N 11.96
found : 61.55, 6.12, 12.02
Example 23.
a) 2-Chloro-6-methoxY-3,7-~ 3$b~
ribofuranosylpurine.
The compound of Example 18b) is heated for 40
hours in lN methanolic sodium methanolate solution.
The reaction product is purified on Amberlite XAD by
hydrophobic chromatography (methanol/water).
UV (methanol): ~ max = 271, 280 nm.
Analysis for C13H15ClN2O4
calc. : C 52 27, H 5.U6, Cl 11.87, N 9.38
found : 52.24, 5.14, 12.05, 9.46
.

-50-
b) 2-Chloro-3,7-didesaza-2'-desoxy-9-~-D-ribo-
furanosyl~urin 6-one.
Heating the compound of Example 18b) for 30 hours
in 2N a~ueous sodium hydroxide solution/la4-dioxan gives
the desired compound.
UV (methanol): ~ max = 262 nm
Analy8iS for C13H16N24
calc. : C 59.08, H 6.10,N 10.60
fuund : 59.09, 6.07,10.65
lH-NMR ([D6]DMSO): ~ = 2.22 (m, 2'-Hb)3 2.38 (m, 2'-Ha),
3.53 (m, 5'-H2)~ 3.30 (m, 4'-H), 4.33 (m, 3'-~I), 4.96
(5'-OH) 9 5.29 (3'-OH), 6.22 (pt, l'-H), 6.54 (d, J =
3 Hz, 3-H)~ 6.96 (s, 7-H), 7.33 (d, J - 3 Hz, 2-H); 11.81
(NH).
Example 24.
a) 4-Chloro-7 (2l-desoxy-3,5-di-0-(p-toluoyl)-~-D-
er~thro~entofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine.
1 g. (17.8 mMole) powdered potassium hydroxide is
introduced at ambient temperature into 60 ml. dry
acetonitrile. 100 ~1. (0.31 mMole) tris-[2-(2-methoxy-
ethoxy)-ethyl~-amine.are added thereto, while stirringO
-~ A~ter 5 minutes) 1.23 g. (8.01 mMole) 4-chloro-7~-
pyrrolo[2,3-d]pyrimidine are dissolved in the reaction
mlxture which is stirred for a further 5 minutes.
~; ; 25 a-Chloro-2-desoxy-3,5-di-0-p-toluoyl-~-D-erythro-pento-
furanose is th~n added thereto. After stirring ~or 15
minutes, insoluble material is removed by filtration.
-
.

-51-
The filtrate is evaporated to dryness in a vacuum and
the residue chromatographed on a silica gel column
~5 x 7 cm., chloroforr~l). After evaporation o~ the
eluate in a vacuum there are obtained 3.26 g. (~1% of
theory) of product which crystallises from ethano] in
the form of colourless needles; m.p. 120C.
Further variants of the process of preparation:
(I) Solid-liquid glycosilation in the absence of a
catalyst. The reaction is carried out as described
above but without the use of a catalyst. After working
up~ ~here are obtained 2.82 g. (70% of theory) of the
product.
(II) By liquid-liquid phase trans~er glycosilation:
500 mg. (3.26 mMole) 4-chloro-7H-pyrrolQ[2,3-d]
pyrimidine are dissolved in 20 ml. dichloromethane.
9 ml. of 507O aqueous sodium hydroxide solution are
;~ added thereto. After the addition of 10 mg. (0.03
mMole) tetrabutylammonium hydrogen sulphate, the
solution is stirred for 1 minute with a vibratory mixer.
Subsequently 9 1 ~ 4 g. (3.61 mMole) of the above-described
halogenose is added thereto and mixing continued for a
further 3 minutes, whereafter the phases are separa~ed.
The aqueous phase is extracted twice with, in each case,
25 ml, dichloromethane. The combined organic phases
are dried over anhydrous sodium sulphate. The filtrate
is evaporated to dryness and the residue is chromato-
graphed on silica gel (column 5 x 5 cm., chloroform).
,
.

-52-
Isolation of the product from the main fraction and
crystallisation from ethanol gives 1.04 g. (63% of
theory) of the desired product; m.p. 118C.
TLC (cyclohexane/ethyl acetate 3:2 v/v): Rf = 0.7.
U~ (methanol): ~ max = 240 nm (log ~ = 4.48).
lH-N~R (DMSO~d6): ~ = 2.37, 2.40 (s, 2 CH3), 2.77 (ml
2'-Hb), 3.18 (m, 2'-Ha), 4.60 (m, 4'~H and 5'-H), 5.77
(m; 3'-H), 6.75 (d, J = 3.7 Hz, 5-H), 6.78 (m, l'-H),
7.34, 7.91 (m, 8 aromat. H and 6-H), 8.65 (s, 2-H).
b) 4-Chloro~7-(2'-desoxy-~-D-erythro-pentofuranosyl)-
- 7H-pyrrolo~2,3-d]pyrimidine.
2.4 g. (4.7 mMole) of the compound of Example 24a)
are stirred ~or 24 hours at ambient ~emperature in
100 ml~ methanol saturated with ammonia. The solution
is evaporated to dryness, ~he residue is adsorbed on
10 g. silica~gel 60 H and applied to a silica gel column
(4 x 10 cm.~ chloroform/methanol 95:5 v/v). The product
is isolated froDl the main fraction as a colourless,
~olid substance which crystallises from ethyl acetate as
colourless needles. Yield 1.07 g. (84% of theory);
m.p. 162C.
TLC (chloroorm/methanol, 9:1 v/v): ~f = 0.6.
UV (methanol): ~ max = 273 mn (log ~ 3.69).
.
H-NMR (DMSO-d6): ~ = 2.28 (m, 2'-Hb), 2.53 (m, 2'-Ha),
3.57 (m, 5'-H), 3.87 (m, 4'-H), 4.40 (m, 3'-H), 5.00
~; (t, J = 5.4 Hz, 5'-OH), 5.35 (d, J = 4.2 Hz, 3'-OH),
6.66 (m, l'-H), 6.72 (d, J = 3.8 Hz, 5-H), 7.99 (d, J =
3.8 Hz, 6-H), 8.66 (s, 2-H).
,
,
.,

~ 3 ~
-53-
c) 4 Chloro-7-(2'-desoxy-~-D-erythro-pentofuranosyl)-
5'-0-(4,4'-dimethoxytrityl)-7H pyrrolo~2.3 d]-
py~imidine.
1 g. (3.7 mMole) of the compound of Example 24b)
is dried by evapora~ing with lO ml. dry pyridine. The
material is dissolved in 20 ml. dry pyridine. 2 ~nl.
(11.7 mMole) Hunig's base and 2 g. (5.9 mMole) 434'-
dirnethoxytrityl chloride are added thereto. The solution
is stirred for 3 hours a~ ambient temperature. After the
addition of ~0 ml. 5% aqueous sodium bicarbonatP solution,
the solution is extrac~ed three times with 100 ml.
amounts of dichloromethane. The combined organic phases
are dried over anhydrous sodium sulphate. After
; filtering off, ~he filtrate is evaporated in a vacuum.
The residue is purified by column chromatography (silica
gel, elution agent dichloromethane and dichloromethane/
ethyl acetate 9:1 v/v). Isola~ion of the product from
the main ~raction, dissolving in diethyl ethPr and pre-
cipitation with petroleum ether gives 1.66 g. (78% of
theory) of the desired product in the form of a yellowish
amorphous substance.
Analysis ~or C32H30N305Cl (M.W. 572.1)
calc. : C 67.19, H 5.29, Cl 6.20, N 7.35
, .
found : 67.03, 5.47, 6.19 7.29
TT,C (dichloromethane/acetone 9:1 v/v): R~ = 0.3.
UV (methanol): ~ max = 274 nm (log ~ = 3.~5).
,

t~
-5~-
lH-NMR (DMSO-d~): = 2.36 (m, 2l-Hb), 2.70 (m, 2'-Ha),
3.72 (s, OCH3) 9 3.18 (d, J = 4.5 I-lz, 5'-H), 3.99 (m,
4'-H), 4.45 (rn, 3'-H), 5.42 (d, J = 406 Hz, 3'-OH),
G.65 (m, l'-}~), 6.69 (d, J = 3.7 Hz~ 5-H), 7.81 (d,
5 J = 3.7 Hz, 6-H), 8.64 (s, 2-H).
d) 4-Chloro-7-(2'-desoxy-~-D-erythro-pentofuranosyl)-
5'-0-(4,4'-dimethoxytrityl)-3'-0-phenoxythiocarbony~
7H-pyrrolo~2,3-d]pyrimidine.
1 g. (1.7 mMole) of the compound of Example 24c)
is dissolved in 30 ml. dry acetonitrile, 500 mg. (4.1
mMole) 4-dimethylaminopyridine and 400 ~l. (2.9 mMole)
phenyl chlorothiocarbonate are added thereto and the
solution is stirred for 16 hours at ambient temperature.
Subsequently, the reaction mixture is evaporated to dry-
ness in a vacuum and the residue applied to a silica gel
column (3 x 15 cm., dichloromethane). From the main
fraction, there are isolated 950 mg. (76% of theory) of
colourless, amorphous product.
Analysis for C3~H34ClN306S (M.W. 708.2)
calc. : C 66.14, H 4.84, Cl 5.al~ N 5.93, S 4.53
found : 66.22, 4.94, 5.12, 5.93, 4~46
~ TLC (dichloromethane/acetone 95:5 v/v): Rf - 0.8.
;~ UV ~methanol): ~ max = 274 nm (log = 3.87).
H-NMR (DMSO-d6): ~ = 2.84 (m, 2l-Hb)~ 3.21 (m, 2'-Ha)~
3.37 (m, 5'-H), 4.46 (m, 4'-H), 5.92 (m, 3~-H), 6~70
(m, l'-H), 6.76 (d, J = 3.8 Hz, 5-H~, 7.85 (d, J =
3.g H2, 6-H~, 8.61 (s, 2-H).

2 ~ ~
-55-
e) 4-Chloro-7-(2',3'-didesoxy-~-D-~lyceropento-
furanosyl)-5'-0-(4,4'-dimethoxytrityl)-7H-pyrrolo-
[2J3-d]p~rlmidine.
800 mg. (1.1 mMole) of the compound of Example 24d)
and 40 mg. (0.2 mMole) 2,2'-azo-bis-(2-methyl)-propio-
nitrile are dissolved in 40 ml. dry toluene under an
atmosphere of a~gon. 600 ~1. (2.2 mMole) tri-n-butyl
stannane are added thereto, while stirring, and the
reaction is continued for 2 hours at 75C. The solvent
is removed in a vacuum and the residue chromatographed
on silica gel (column 15 x 3 cm., dichlorQmethane/ethyl
acetate 95:5 v/v). From the main fraction, there are
obtained 470 mg. (75% of theory) of the desired product.
Analysis for C32H30ClN304 (M.W. 556.1)
calc. : C 69.12, H 5.44, Cl 6.38, N 7.56
ound : 69.07, 5.53, 6.33, 7~58
TLC (dichloromethane/acetone 95:5 v/v): Rf = 0.5.
UV (methanol): ~ max = 273 nm (log = 3.78).
H-NMR (DMSO-d6): ~ = 2.08 (m, 3'-H), 2.10 (m9 2'-Hb),
2.43 (m, 2'-Ha), 3.11 (d~ J = 4.4 Hz, 5'-H), 3.71 (S3
OCH3), 4.27 (m, 4'-H), 6.55 (dd, J = 3.6 and 6.9 Hz,
H), 6.64 (d, J = 3.7 Hz, 5-H)~ 7.83 (d, J = 3.7 Hz,
6-H), 8067 (s, 2-H).
f) 4-Chloro-7-(2',3'-didesoxy-~-D-~lyceropento-
furanosyl)-7H-pyrrolo[2,3-d]~yrimidine.
400 mg. (0.7 mMole) of the compound of Example
24 e)are diFsolved in 15 ml. 80% aqueous acetic acid and
~ . .
~,
:
,

-56-
stirred for 30 minutes at ambient temperature. Th~
solvent is removed in a vacuum and traces of acetic acid
are removed by evaporation with water. The residue is
purified by column chromatography (dichloromethane and
dichloromethane/methanol 3 ~8 2 v/v)- From the main
fraction there are obtained 120 mg. (67% of theory) of
produc~ which, after crystallisation from ethyl acetate 9
is ob~ained in the form of colourless needles; m.p.
90C .
Analysis ~or CllH12ClN302 (M.W. 253.7)
calc. : C 52.08, H 4.77, Cl 13.98, N 16.56
found : S2.20, 4.81, ~ 14.04, 16.54
TLC (dichloromethane/methanol 95:5 v/v): Rf = 0.5.
UY (methanol): ~ max = 274 nm (log = 3.65).
lH-NMR ~DMS0-d6): S = 2.04 (m, 3'-E), 2.28 (m, 2'-Hb),
2.46 (m, 2'-Ha), 3.57 (m, 5' H)~ 4.11 (m, 4'-H), 4.95
(t, J = 5.5 Hz, 5'~OH), 6.52 (dd, J = 3.8 and 6.~ Hz,
~ H), 6.69 (d, J = 3.8 Hz, 5-H)~ 8.01 (d, J = 3.8 ~z,
;~ 6-H), 8.64 (s, 2-H).
~-20 g) 7-(2',3'-Didesoxy-~-D-glyceropentofuranosyl)-
7H-pyrrolo[2,3-d]pyrimidine.
A solution of 200 mg. (0.8 mMole) of the compound
of Example 24f) in 20 mlO methanol, to which had been
added 0.5 ml. (6.6 mMole) of concentrated aqueous ammonia
solution, is stirred with palladium on animal charcoal
(40 mg., 10% Pd) in an atmosphere of hydrogen at ambient
-temperature or 3 hours. The catalyst is iltered of
~ :'
:~, : '' ' ' ' '
'

2 ~ ~
-57-
and the solvent removed in a vacuum. The residue îs
dissolved in water and chromatographed on an Amberlite
XAD-4 column (lst elution agent water, 2nd elution agent
water/methanol 8:2 v/v). Isolation of the product from
S the main zone gives 130 mg~ (75% of theory) of the
colourless product in the form of needles; m.p. 131C.
Analysis for C~ 132 3
calc. : C 60.26, H 5.98, N 19.17
found : 60.19, 5.97, 19.18
TLC (dichloromethane/methanol 9:1 v/v): Rf = 0.6.
UV (methanol): ~ max = 270 nm (log ~ = 3~56)~
lH-NMR (DMSO-d6): ~ = 2.06 (m, 3'-H)~ 2.27 (m, 2'-Hb),
2.42 (m9 2'-Ha), 3.55 (m, 5'-H), 4.09 (m, 4~-H)~ 4.93
~;~ (t, J = S.5 Hz, 5'-OH), 6.54 (dd, J = 4.3 and 6.9 Hz,
l~-H)s 6.67 (d, J = 3.7 Hz, 5-H)~ 7.86 (d, J = 3.7 Hz,
6-H), 8.79 (s~ 4~H), 9.01 (s, 2-H).
hj 4-~ no-7-(2',3'-didesoxy~-D-~ly~eropento-
furanosyl)-7H-pyrrolo[2,3-d]pyrimidine (2~,3'-dideoxy-
tubercidin)
~: f~ 20 200 mg. (0.8 mMole) of the compound of Example
24f) are stirred in 60 ml. 257 aqueous ammonia solution
for 15 hours at 100C. under pressure in a steel bomb.
Th solvent is subsequently removed in a vacuum and the
residue dissolved in 200 ml. water. This solution is
puriied on 3Owex 1 x 2 (OH form). Th~ column i5
washed with water and the product eluted with water/
methanol (9:1 v/v). From the main zone are obtained
. . ~

-58-
120 mg. (6570 of theory) of produc~.
; Tl,C tdichloromethane/methanol 9:1 v/v): Rf = 0.3.
lH-NMR (DMSO-d6): ~ = 2.03 (m, 3'-H), 2.22 (m~ 2'-Ha)~
2.33 (m, 2'-Hb), 3.53 (m, 5'-H), 4.04 (m, 4'-H), 4.99
(m, 5'-OH3, 6.35 (m, l'-H), 6051 (d, J = 3.6 Hz, 5~H),
7.00 (s, NH2), 7.34 (d; J = 3.6 Hz, 6-H), 8.04 (g, 2-H).
i~ 7-(2',3'-Didesoxy-~-D~~lyceropentofuranosYl)-4-
me~hoxy-7H-pyrrolol2,3-d]p~rimidine.
170 mg. (0.7 mMole) of the compound of Example 24f)
are dissolved in 5 ml. ]M methanolic methanolate solution
and stirred at ambient temperature for 4 hours. The
solution is neutralised with 80% acetic acid, evaporated
in a vacuum and the residue applied to a silica gel
column (elution agent dichloromethane/methanol 98:2 v/v).
Isolation of the main zone gives a colourless oil which,
upon storing, crystallises in the form of needles.
Yield 130 mg. (78% of theory).
jj 7-(2'~3'-D _esoxv-~-D-glyceropentofuranosyl)-4H-
pyrrolo[2,3-d_~yrimidin-4-one.
200 mg. (0.8 mMole) o~ the compound of Example
24f) are suspended in l0 ml~ 2N aqueous sodium hydroxide
solution and boiled under reflux fox 5 hours. The
solution is neutralised with 80% acetic acid and the
insoluble material is removed by filtration. The
iltrate is applied to an Amberlite XAD-4 column. The
~-~ eolumn is washed with 500 ml. of water and the produc~
eluted with water/isopropanol (9:1 v/v). There are
~'
:
;:

2 ~ ~
-59-
obtained 180 mg. (80% of theory) of product.
Example 25.
1-(2',3'-Didesoxy-~-D-glyceropentafuranosyl)-lM-
pyrazolol3.4-d]pyrimidin-4-one.
The produc~ of Example 17d) is deaminated with
adenosine deaminase from intestinal c:al-f mucosa cells.
The progress of the reaction is moni~ored UV spec~ro-
scopically at 275 nm. The reaction gives the produc~
quantitatively in the form o~ colourless crystals;
m.p. 171C.
UV (methanol): ~max = 251 nm ( = 7700)
; TLC (silica gel, dichloromethane/methanol 9:1 v/v):
; R~ = 0.5.
3C-NMR ([D6]DMSO): ~ = 135.2 (C-8), 106.1 (C-5),
157.3 ~C-6), 14~.4 (C-2), 152.3 (C-4), 84~6 (C-l'),
~` 30.7 (C-2l), 27.3 (C-3'), ~2.2 (C 4'), 64.2 (C-5').
H-NMR ([D6]DMSO): ~ = 2.13 (m, 3'-H), 2.40 (m, 2'-H),
3~40 (m, 5'-H), 4.09 (m, 4t-H), 4.73 (m, 5'-OH), 6.43
(m, l'-H), 8.11 (s, 3-H), 8.13 (s, 6-H).
Example 26.
2-Amino-7-desaza-2',3'-didesoxy-9-~-D-ribofuranosyl-
purin-6-one 5'-triphos~ate.
Analy8is ~or CllH14H4~2P3Na3
calc. : P 16.7
found : 16.4
UV (bufer9 pH 7 ): ~ max = 259 nm ( = 13400)
:

~3~ ~2~
..
-60-
31P-NMR (D203~ 8.35 (d, P-Y), -10.0 (d, P~
-21.5 (t, P-~).
Example 27.
2-Amino-3,7-didesaza-2'-desoxy-9-~-D-ribofuranosyl-
_
purin-6-one 5'-triphosphate.
AnalysiS fo~ C12H15N313P3 3
calc. : P 16.75
found : 16.5
UV (buffer, pH 7 0): A ma~ = 272 nm (~ ~ 12400).
Example 28.
3,7-Didesaza-2',3'-didesoxy-9-~-D-ribofuranosylpur:ine
5'-triphosphate.
AnalySis for C12H14N2llP3Na3
calc. P 17.7
: 15 found : 17.3
- UV (buffer, pH 7 0): ~max. 2
All of ~he triphosphates described in Examples
26 to 28 are prepared by phosphorylation of the corres-
ponding nucleosides by the method described by
Yoshikawa (Tetrahedron Letters, 50, 5065/1967) to give
: .
he 5'-monophosphates and subsequen~ conversion into the
5'-~riphosphates by the method of Hoard and Ott
. (J.A C.S., 87, 1785/1965).
`~ Exam~ 29.
:~; 25 Antiviral _ iVitY.
The stability of the N-glycosidic bond of 2',3'-
didesoxynucleosides i9 bound up with the antivlral
.

-61-
activityO
The hydrolysis of the bond was investigated at
25C. in three difEerent concentrations of hydrochloric
acid. For this purpose~ the UV absorption (Et) was
measured at 258 nm. Via ~he absorption/time cur~e,
there were determined the velocity constants of the
hydrolysis (k) and the half life times (T/2) on the basis
of the following equation:
k = l/t x ln (Eo - Eoo)/(Et OO
EO b~ing ~he absorption at time t = 0 and Eoo being the
absorption after complete termination of the reaction.
There were compared 2'93'-didesoxyadenosine (a)
and 6-amino~8-aza-7-desaza-2',3'-didesoxy-4-~-D-
ribofuranosylpurine (b) at 25C. The results obtained
lS are set out in the following Table:
Table
_
~ lN HCl O.lN HCl O.OlW HCl
~ ~ _ _
(a) T/2 - l1.9 min. 31.5 min.
k _ 0.363 min l 0.022 min l
(b) T/20.83 min. 20.4 min. 2~0 min.
_ k 0.85 min~l ~,033 ~ 0.0025 min 1
The above Table shows that the compound (b~ accord-
ing to the presen~ invention is more than 10 times more
stable and thus more antivirally effective than (a).
' :~
'

Representative Drawing
A single figure which represents the drawing illustrating the invention.
Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 2009-12-08
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Grant by Issuance 1992-12-08

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
BOEHRINGER MANNHEIM GMBH
Past Owners on Record
FRANK SEELA
HANS-GEORG BATZ
HEINZ-PETER MUTH
HERBERT VON DER ELTZ
KLAUS KAISER
KLAUS MUHLEGGER
WERNER BOURGEOIS
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1993-11-08 12 312
Cover Page 1993-11-08 1 32
Abstract 1993-11-08 2 43
Drawings 1993-11-08 1 16
Descriptions 1993-11-08 62 2,031
Representative drawing 2000-08-16 1 2
Fees 1995-11-20 1 71
Fees 1996-11-18 1 62
Fees 1994-11-13 1 65